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Spinocerebellar ataxia type 1 (SCA1) is a late-onset neurodegenerative disease caused by 
expansion of the polyglutamine (polyQ) tract in Ataxin-1 protein (Atx1). The cellular 
mechanisms of how the altered function of Atx1 causes progressive neurodegeneration of the 
cerebellum are still not fully understood. Zebrafish (Danio rerio) is a powerful organism for in 
vivo bioimaging of disease mechanisms and compound studies. Therefore, this study aimed to 
establish a genetic model of SCA1 in zebrafish accessible for observing affected Purkinje cells 
(PCs) using fluorescent protein reporters and biosensors and for monitoring the behavioral 
performance of affected fish in relation to their disease progression. Three stable transgenic 
zebrafish strains were generated expressing the membrane-targeted red fluorescent reporter 
GAPmScarlet only or together with the human protein Atx1 (30Q or 82Q) in bidirectional 
DNA constructs under control of a PC-specific enhancer. These strains were subjected to long 
term in vivo monitoring of PC degeneration. They were also subjected to calcium imaging at 
larval stages. Furthermore, long term behavioral analysis was performed.  
The SCA1 zebrafish strain expressing Atx1[82Q] developed a larval cerebellum 
indistinguishable from the control strains. However, calcium-transient activity revealed onset 
of PC abnormal physiology already evident at 6 and 12 days post fertilization (dpf). Yet an 
age-dependent progressive degeneration of PCs was observed starting at 40 dpf. Although this 
neuropathology did not result in gross locomotor deficits, late juveniles at 2 months post 
fertilization (mpf) as well as adults at 3 mpf with advanced PC loss demonstrated a strongly-
reduced exploratory behavior. However, early juvenile SCA1 fish at 40 dpf did not display 
behavioral deficits probably due to less-pronounced PC degeneration. This novel SCA1 
neurodegeneration model in zebrafish, mimicking human SCA1 pathology, is a powerful tool 
to reveal the causative mechanisms of cytotoxicity in vivo. Moreover, this model can be used 
for validating candidate compounds against such a devastative neurological disease for their 






Die spinozerebelläre Ataxie Typ 1 (SCA1) ist eine spät auftretende neurodegenerative 
Erkrankung, die durch eine Expansion des Polyglutamin-Trakts (polyQ) im Ataxin-1-Protein 
(Atx1) verursacht wird. Die zellulären Mechanismen, wie die veränderte Funktion von Atx1 
eine fortschreitende Neurodegeneration des Kleinhirns verursacht, sind noch nicht vollständig 
verstanden. Der Zebrafisch (Danio rerio) ist ein leistungsfähiger Organismus für das in vivo 
Bioimaging von Krankheitsmechanismen und Wirkstoffstudien. Daher zielte diese Studie 
darauf ab, ein genetisches Modell von SCA1 im Zebrafisch zu etablieren, das für die 
Beobachtung betroffener Purkinje-Zellen (PC) mit Hilfe von Fluoreszenzprotein-Reportern 
und Biosensoren zugänglich ist, sowie für die Beobachtung des Verhaltens betroffener Fische 
in Abhängigkeit von ihrem Krankheitsverlauf. Es wurden drei stabile transgene 
Zebrafischstämme generiert, die den membrangezielten rot fluoreszierenden Reporter 
GAPmScarlet allein oder zusammen mit dem humanen Protein Atx1 (30Q oder 82Q) in 
bidirektionalen DNA-Konstrukten unter Kontrolle eines PC-spezifischen Enhancers 
exprimieren. Es folgten langfristige in vivo Studien der drei Linien mit besonderem 
Augenmerk auf das degenerative Verhalten der Purkinje Zellen, sowohl in Larven als auch in 
adulten Tieren. Hierfür wurden unter anderem Kalzium-Bildgebungsanalysen im 
Larvenstadium und Langzeit-Verhaltensanalysen im Alter von 40 Tagen nach der Befruchtung 
(dpf), 2 und 3 Monaten nach der Befruchtung (mpf) durchgeführt. 
Der SCA1-Zebrafischstamm, welcher Atx1[82Q] exprimierte, entwickelte ein larvales 
Kleinhirn, das sich nicht von dem der Kontrollstämme unterschied. Die Kalzium-
Transientenaktivität zeigte jedoch den Beginn der abnormalen Physiologie des PC bereits am 
6. und 12. dpf. Dennoch wurde eine altersabhängige progressive Degeneration der PCs erst ab 
40 dpf beobachtet. Obwohl diese Neuropathologie nicht zu groben lokomotorischen Defiziten 
führte, zeigten die späten Juvenile im Alter von 2 mpf sowie adulte Fische im Alter von 3 mpf 
mit fortgeschrittenem PC-Verlust ein stark reduziertes Erkundungsverhalten. Die früh-
juvenilen SCA1-Fische im Alter von 40 dpf zeigten jedoch keine Verhaltensdefizite, 
wahrscheinlich aufgrund einer weniger ausgeprägten PC-Degeneration. Dieses neuartige 
SCA1-Neurodegenerationsmodell im Zebrafisch, das die menschliche SCA1-Pathologie 
nachahmt, ist ein leistungsfähiges Werkzeug, um die ursächlichen Mechanismen der 
Zytotoxizität in vivo aufzudecken und besser zu verstehen. Darüber hinaus kann dieses Modell 




Erkrankung hinsichtlich ihrer Wirksamkeit, Nebenwirkungen und Blut-Hirn-Schranken-






















  هبذة خمخرصة
هَح امنُّخاؼي املَُخْيخي من امنوع ألول ىو مرض ؼصيب مذأٔخر امغيور مل يكدشف هل ؽالج حَّت الٓن. يسبب ىذا املرض مضوًرا  مرض امرَّ
بؾض وفقداًًن ثدرجييًّا نوخالَي امؾصبية ِبخمليخ؛ مما يؤدي ٕاىل خول ثدرجيي ِف الاحزان احلريك، ِبَلضافة ٕاىل خول هفيس وٕادرايك ِف 
. 1احلاَلت املخأٔخرة، وينهتيي ِبموفاة. ىذا املرض ًنمج ؼن خول جيِن يؤدي ٕاىل اس خطاةل امسوسةل مذؾددة اجلوواتمني ِف بروثني ٔأاتكسني 
َل حزال الٓميات اخلووية مكيفية جسبب اخلول اموعيفي مػيذا امربوثني ِف حدوث امضمور امؾصيب امخدرجيي نومخيخ غْي مفيوم متاًما. ثؾد 
ْي كة امزرد، بوصفيا َكئنًا حيًّا يمتزي بْيقاثو امشفافة ىف مراحل اهمنو املبكرة، مناس بة نوخصوير احليوي لٓميات ألمراض، وِلراسة ثأٔزمس
املركبات اخملخوفة بوصفيا ؽالجات حممتةل ميذه ألمراض دون احلاجة ٕاىل جرشحييا. ذلكل، هتدف ىذه اِلراسة ٕاىل ٕاوشاء منوذج حيايك مرض 
ثرة هبذا هَح امنُّخاؼي املَُخْيخي من امنوع ألول ِف مسكة امزرد ميكن ؼن طريقو مراقبة خالَي بوركينجي اميت ثؾد ٔأكرث اخلالَي امؾصبية املخأٔ امرَّ 
 .املرض، كام ميكن مراقبة امخغْي امسوويك مٔلسامك املصابة مػ ثقدم املرض
ٔأسامك امزرد املؾدةل ورازًيا َتمل امربوثني امبرشي امطبيؾي ٔأو مسبب املرض ِبس خخدام ثقنيات اميندسة امورازية، ُأهخجت سالَلت من 
داخل خالَي بوركينجي. خضؾت ىذه امسالَلت ملراقبة طويةل املدى ِف ٔأؼامر خمخوفة حَّت امبووغ. متت مراقبة وعيفة خالَي بوركينجي 
اجئ ىذه اِلراسة ٔأن سالةل ألسامك اميت َتمل امربوثني امبرشي وشلكيا، ِبَٕلضافة ٕاىل مراقبة ألداء امسوويك مٔلسامك. مقد موحظ ِف هخ
مسبب املرض َتخوي ؽىل خميخ َل ميكن متيزيه شًلًك ؼن سالةل ألسامك اميت َتمل امربوثني امطبيؾي. ومكن كشفت دراسة وعيفة 
ظ مضور ثدرجيي يزداد مػ ثقدم يوًما. كام موح 11و 6خالَي بوركينجي بوضوح ؼن ضؾف ِف وشاط ىذه اخلالَي امؾصبية ِف َعر 
ا، فقد امؾمرخلالَي بوركينجي بدًءا من َعرألربؾني يوًما. وؽىل امرمغ من ٔأن امسالةل احلامةل ميذا املرض امؾصيب مل ثغير َعًزا حركيًّا كبْيً 
غة ؼند َعر زالزة شيور ٕاىل ٔأدت شدة امضمور وفقدان ُك كبْي من خالَي بوركينجي ِف ألسامك ذات َعر امشيرين وكذكل ألسامك امبام
هَح  اخنفاض شديد ىف امسووك الاس خكشاِف مقارهة بأٔسامك امسالةل غْي احلامةل نومرض. يؾد ىذا اهمنوذج ٔأول منوذج حيايك مرض امرَّ
جي. ؽالوة ؽىل امنُّخاؼي املَُخْيخي من امنوع ألول ِف ٔأسامك امزرد، وىو وس يةل فؾاةل نوكشف ؼن الٓميات املسببة مضمور خالَي بوركين
جلاهبية فؾاميهتا وأآثرىا اؾالجات ميذا املرض امؾصيب من حير ذكل، ميكن اس خخدام ىذا اهمنوذج َلخذبار امؾديد من املركبات املرحشة ك





1.1 Spinocerebellar ataxia type 1 
Spinocerebellar ataxia type 1 is an adult onset, autosomal dominant neurodegenerative disease 
caused by a cytosine-adenine-guanine (CAG)-repeat expansion mutation in the human ataxin-
1 gene (Atx1), resulting in abnormal expansion in the polyQ tract of the Ataxin-1 protein 
(Atx1). This protein contains a polyQ tract of ‎variable length in its N-terminus, with non-
interrupted polyQ-stretches of above 40 glutamine ‎residues leading to SCA1 symptoms and 
neurodegeneration (Nethisinghe et al. 2018). The length of this tract inversely correlates with 
the age of onset and directly correlates with the severity of pathogenesis and progression of 
SCA1 (Zoghbi and Orr 2000). In SCA1 patients, motor coordination, ‎visuospatial 
performance, psychiatric health and cognitive abilities successively decline leading ‎to death 
(Pérez Ortiz and Orr 2018). The symptoms of the disease begin usually in the twenties or 
thirties of age and they get worse in an age-dependent progressive manner (Orr et al. 1993). 
The mutated Atx1 protein causes progressive neurodegeneration of cerebellar PCs which ends 
with atrophy of the cerebellum (Fig. 1.1) and death within 10-30 years after first appearance of 
the disease onset (Pérez Ortiz and Orr 2018; Wang et al. 2016). 
 
 
Figure 1.1 Sagittal MRI from unaffected control (left) and SCA patient (right) 
MRI from a SCA-affected patient reveals cerebellar degeneration and cervical spinal 
cord thinning. Modified from (Wang et al. 2016). 




The length of the wild-type Atx1 protein is 816 amino acids. However, this varies according 
to the length of polyQ tract which is normally 4 to 36 glutamine residues and 38 to 83 
uninterrupted glutamine residues in SCA1-affected patients (Nethisinghe et al. 2018; Rocha et 
al. 2019). The polyQ tract is positioned at the N-terminal region of the protein (starting at 
amino acid 197). In addition, the Ataxin-1 and HMG-box protein 1 (AXH) domain (amino 
acids 570-689) is functional in the interactions of the Atx1 protein either with itself or with 
the most of the Atx1 interactors (Chen et al. 2004; Goold et al. 2007; Zoghbi and Orr 2009). 
Furthermore, the nuclear localization signal (NLS) (amino acids 771-776) is the responsible 
signal for Atx1 translocation into the nucleus. The C-terminal residue of the NLS contains 
serine residue (Ser
776
) which can be phosphorylated by the kinases (Klement et al. 1998; 
Zoghbi and Orr 2009) (Fig. 1.2). The function of the human Atx1 protein is not fully 
understood so far (Nethisinghe et al. 2018). However, it has been shown that Atx1 is involved 
in motor coordination, cognitive function and β-amyloid precursor protein (APP) processing 
(Matilla et al. 1998; Crespo-Barreto et al. 2010; Zhang et al. 2010). It plays a role in 
transcriptional regulation and RNA metabolism (Matilla-Dueñas et al. 2008). Atx1 is also 
required for remodeling of extracellular matrix through forming a transcriptional repression 
complex with the transcriptional repressor Capicua (Lee et al. 2011). 
 
 
Figure 1.2 Human Ataxin-1 protein 
Structural and functional domains of Atx1 protein. AXH, NLS and aa stand for Ataxin-
1 and HMG-box protein 1, nuclear localization signal and amino acids, respectively. 
Modified from (Chen et al. 2004; Chiara et al. 2009; Rocha et al. 2019; Zoghbi and 
Orr 2009). 
 
Formerly, some highly-informative studies have been accomplished to reveal causal 
mechanisms of the SCA1 ‎pathology. However, the knowledge of the cellular and molecular 
mechanisms underlying SCA1-‎mediated neurodegeneration is still incomplete. Thus, no 
treatment is existent for SCA1 disease, and cure is limited to symptom amelioration.‎ SCA1 
disease is characterized by the presence of large inclusion bodies of the mutant polyQ Atx1 in 
the nuclei of affected neurons (Zoghbi and Orr 2009). These protein aggregates play a 




Polyglutamine tract AXH domain 




significant role in the polyQ-caused pathogenesis (Taroni and DiDonato 2004). Moreover, the 
abnormal polyQ expansion in the Atx1 protein induces its pathogenesis by altering the 
interactions of Atx1 with its interactor proteins (Nethisinghe et al. 2018). Thus, both protein 
aggregation as well as abnormal protein interactions are the polyQ-mediated pathogenic 




Figure 1.3 Schematic model of SCA1 pathology 
The pathogenic pathways leading to cytotoxicity in SCA1 are protein aggregation 
and abnormal protein interactions (Kang and Hong 2009). 
 
Wild-type Atx1 is present in the cell in two large protein complexes at least. In the first 
complex, Atx1 is bound to the transcriptional repressor Capicua (CIC) and it is not 
phosphorylated at Ser
776
 phosphorylation site. In the other complex, Atx1 is bound to the 
RNA splicing regulator mRNA-binding motif protein 17 (RBM17) and phosphorylated at 
Ser
776
 site (Fig. 1.4A). However, in case of the mutant Atx1 with abnormally-expanded polyQ 
tract, an imbalance of the two complexes occurs in which less Atx1 is bound to CIC and more 
Atx1 is associated with RBM17 (Fig. 1.4B). Both the expansion of the polyQ tract and the 
phosphorylation of Ser
776
 increase the interaction of Atx1 with RBM17 (Zoghbi and Orr 
2009). Consequently, it is suggested that SCA1 pathogenesis is caused by both a gain-of-




the entire loss of Atx1 did not induce SCA1 pathogenesis (Matilla et al. 1998). Taken 
together, it may be that the core reason of SCA1 pathogenesis is a gain-of-function 




Figure 1.4 Illustration of the abnormal protein interactions in SCA1 
The abnormal expansion of the polyQ tract alters the balance of Atx1 protein 
complexes: 
(A) Wild-type Atx1 is either bound to the transcriptional repressor Capicua (CIC) and not 
phosphorylated at Ser776 site, or bound to the RNA splicing regulator mRNA-binding 
motif protein 17 (RBM17) and phosphorylated at Ser776 site. 
(B) Mutant Atx1 with abnormally-expanded polyQ tract shows imbalance in protein 
interactions with less Atx1 bound to CIC and more Atx1 associated with RBM17. 
The orange shape represents Atx1 protein and the violet circles represent glutamine 
residues (Zoghbi and Orr 2009). 
 
Interestingly, pathology of the mutant Atx1 protein does not depend only on the abnormally-
expanded polyQ tract in the N-terminal region of the protein, but also on some domains in the 




Atx1 AXH domain is crucial for its interactions with transcriptional factors (Kim et al. 2013). 
These interactions are affected in case of the mutant Atx1 resulting in cytotoxicity. 
Furthermore, NLS which triggers Atx1 translocation into the nucleus plays an important role 
in the pathogenesis of the mutant Atx1 as it was proven in previous studies that the mutant 
Atx1 induces its toxicity in the nuclei of the affected cell, where it interacts with the 
transcription and RNA processing regulators (Nóbrega and Pereira de Almeida 2018). This 
was confirmed when the human mutant Atx1[82Q] protein with a non-functional NLS was 

















1.2 Genetic modeling of the SCA1 disease 
The current knowledge about cellular and molecular mechanisms underlying SCA1 pathology 
is basically derived from modeling this disease in mouse, fruit fly and cell culture, taking 
advantage of the specific benefits of these models. For instance, transgenic mouse models 
have been an influential tool to understand molecular mechanisms of PC cytotoxicity and 
neurodegeneration as well as the subsequent behavioral deficits in the SCA1-affected mice, 
with the observed phenotypes mimicking those of SCA1 human patients (Burright et al. 1995; 
Emamian et al. 2003; Tsuda et al. 2005). After identification of the SCA1 causative gene, 
which is ataxin-1 (Zoghbi et al. 1991; Ranum et al. 1991), and the gene’s mutation involved 
in the protein’s dysfunction, which is abnormal expansion of CAG repeats coding for the 
polyQ tract in the Ataxin-1 protein (Orr et al. 1993), the first SCA1 animal model was 
established by generating a stable transgenic mouse model of neurodegeneration. 
Referring to the first SCA1 animal model, the human mutant Atx1[82Q] gene with an 
expanded polyQ tract was expressed in mice PCs under the control of the PC-specific pcp2 
promoter. In addition, Burright and coworkers (1995) established control transgenic mice 
expressing the human non-pathogenic Atx1[30Q] gene with a polyQ sequence of normal 
length (Burright et al. 1995). It was reported that the human pathogenic gene with 
abnormally-expanded sequence of CAG repeats could induce PC neurodegeneration (Fig. 1.5) 
and ataxia in mice when expressed in their PCs. However, expression of the human non-
pathogenic gene Atx1[30Q] in mice PCs did not produce neither PC degeneration nor ataxic 
phenotype in the transgenic mice. In conclusion, it was demonstrated that this established 
SCA1 mouse model expressing human SCA1 gene offers an in vivo model for studying the 
cellular and molecular disease mechanisms as well as testing potential therapeutic approaches 











              
Figure 1.5 Purkinje cell morphology in unaffected control mouse (left) and transgenic 
mouse model of SCA1 (right) 
Immunohistochemical antibody staining against calbindin (PC marker) in brain 
sections from 17-week-old mice reveals neurodegeneration of PCs and disorganized 
PC layer in the SCA1-affected mice (right) compared with the typical appearance of 
cerebellar cortex in the healthy control mice (left) (Burright et al. 1995). 
 
Afterwards, further trials to model SCA1 disease in experimental animals were performed 
aiming at obtaining a more precise simulation of the human disease. For example, Watase and 
coworkers (2002) argued that the previously-established SCA1 mouse model (Burright et al. 
1995) displayed only a phenotype related to the deficiency of Purkinje neurons and lives a 
normal lifespan. In their point of view, this model expressing the human mutant Atx1[82Q] 
gene in PCs is different from SCA1-affected human patients who not only show progressive 
impairment of motor coordination due to neurodegeneration of PCs, but also progressively 
develop cognitive deficits, ending up with a complex stage of the disease which leads to 
earlier death. Instead, it was hypothesized that introducing the human mutation into the 
corresponding mouse gene through a knock-in strategy would offer a more accurate model; 
since the gene expression from the endogenous locus should provide precise temporal and 
spatial expression patterns (Watase et al. 2002). 
Therefore, knock-in transgenic mice carrying either 78 or 154 CAG repeats through targeting 
the 78Q or 154Q repeat expansion into the mouse Sca1 locus (Lorenzetti et al. 2000) were 
established. The artificially-expanded 154Q repeats were used to enable inducing a robust 
neurodegeneration in the short lifespan of mice. On the one hand, the transgenic mice strain 
Sca1[78Q] did not display a robust phenotype, however, these mice displayed mild and late-
onset behavioral alterations. On the other hand, the transgenic strain Sca1[154Q] successfully 




mimicked several features of the human SCA1 disease, from neurodegeneration (Fig. 1.6A-D) 
to progressive ataxia (Fig. 1.6E) and cognitive impairment, meaning that the Q154 expanded 
tract was long enough to induce the desired disease phenotypes in mice just with the 
endogenous levels of mutated mouse Atx1 and without the need for overexpressing human 
pathogenic Atx1 allele. It was concluded that such a SCA1 mouse model offers a more 
reliable tool to understand the disease pathological mechanisms and to investigate promising 




Figure 1.6 Phenotypes of a SCA1 knock-in mouse model 
(A-D) Immunostaining against calbindin (PC marker) in brain sections from 34-week-
old mice reveals neurodegeneration of PCs and changed cerebellar morphology in 
the SCA1-affected mice (A, B) compared with the control mice (C, D) to the typical 
appearance of cerebellar cortex in the healthy control mice. Scale bar: 100 µm. 
(E) Ataxic phenotype in a SCA1-affected mouse (left) compared with a healthy 
control mouse (right). 
Modified from (Watase et al. 2002). 
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Furthermore, some SCA1 mouse models were generated with certain genetic characteristics in 
order to investigate specific pathway/s involved in the SCA1 pathology. A clear example for 
this kind of modeling is the transgenic mouse expressing the mutant allele Atx1[82Q]-A
776 
instead of the original human mutant Atx1[82Q]-Ser
776
 allele (Emamian et al. 2003). In this 
SCA1 mouse model, the human mutant Atx1[82Q] allele was overexpressed in Purkinje 
neurons after the serine residue at the position 776 (Ser
776
), the phosphorylation site of the 
Atx1 protein (see Fig. 1.2), was replaced by an alanine residue at the same position (A
776
) to 
enable understanding the role of phosphorylation of Atx1 in SCA1 pathogenesis. Since the 
transgenic mice expressing Atx1[82Q]-A
776 
displayed a significantly-weaker disease 
phenotype with a robust decrease in the ability of the pathogenic Atx1 protein to aggregate and 
form inclusion bodies in the nuclei of PCs (Fig. 1.7), it was suggested that the phosphorylation 
site Ser
776
 of Atx1 plays a vital role in SCA1 pathology together with the abnormally-
expanded polyQ tract and the targeted localization of Atx1 into the nuclei of PCs (Emamian et 
al. 2003). 
 
Figure 1.7 Atx1[82Q]-A776 shows a decreased rate of formation of nuclear inclusions in 
Purkinje cells of a transgenic mouse model of SCA1 
The SCA1-affected transgenic mice expressing the human pathogenic Atx1[82Q]-
A
776 allele with a mutated phosphorylation site display a reduced ability of the 
pathogenic Atx1 protein to form nuclear inclusions in PCs compared to the SCA1-
affected transgenic mice expressing the human pathogenic Atx1[82Q]-Ser776 allele 
with a normal phosphorylation site, demonstrating the importance of the 




In addition to the mouse models, a Drosophila model for SCA1 disease was generated 
(Fernandez-Funez et al. 2000). In order to generate this SCA1 disease model in Drosophila, 
either the non-pathogenic Atx1[30Q] or the pathogenic Atx1[82Q] human alleles were 
expressed in the eye retina of transgenic flies. It was shown that not only the expression of 
Atx1[82Q], but also the quite high expression of Atx1[30Q] could produce disease 
phenotypes. This retina degeneration model in fruit fly has provided rapid screening for genes 
involved in mediating Atx1Q-induced cell death (Fernandez-Funez et al. 2000; Tsuda et al. 
2005). While in Drosophila SCA1 needs to be modeled in heterotypic cell populations due to 
the lack of a cerebellum in invertebrates, mice find their limitations in longitudinal in vivo 
studies for monitoring disease progression, such as in vivo time-lapse microscopy of dynamic 
cell biological processes. Therefore, a genetic model of SCA1 in cerebellar PCs of a 
vertebrate accessible for high resolution in vivo microscopy as well as behavioral and 
















1.3 The zebrafish cerebellum  
The cerebellum, the foremost affected part by the SCA1 disease, is part of the vertebrate brain 
derived from the dorsal region of the anterior-most hindbrain (Hibi et al. 2017). It functions in 
motor control and learning, in addition to higher emotional and cognitive functions. It is 
important for the integration of sensory perception and motor coordination (Bae et al. 2009). 
The structure of its neuronal circuitry is highly conserved among vertebrates. In teleosts, 
nearly all cell types of the human cerebellum can be found displaying a highly-conserved 
morphology, connectivity and function (Hibi and Shimizu 2012; Matsui et al. 2014). 
However, there are a few differences between teleost and mammalian cerebellum. Mainly, the 
mammalian cerebellum lacks eurydendroid cells (ECs) and, in its place, the deep cerebellar 
nuclei (DCN) play a functionally-homologous role, as they receive the axons of PCs with 
inhibitory signals and send efferent axons outside the cerebellum. The DCN are located 
ventrally, far from PCs, whereas ECs are located in the vicinity of the PC region (Namikawa 
et al. 2019a). PCs of the cerebellum are among the most vulnerable ‎neuronal populations that 
are affected by SCA1 cytotoxicity (Zoghbi and Orr 2009). They are GABAergic inhibitory 
neurons discovered by the anatomist Jan Evangelista Purkyně in 1837 (Gruol et al. 2016; 
Chang et al. 2020). PCs are among the brain's largest neurons and they play the key role in 
cerebellar computations (Purves et al. 2001; Chang et al. 2020). 
The zebrafish cerebellum consists of three domains: the valvula cerebelli (Va), the corpus 
cerebelli (CCe) and the lobus caudalis cerebelli (LCa), from rostral to caudal. As in mammals, 
the Va and CCe consist of three layers: the molecular layer (ML), the Purkinje cell layer 
(PCL) and the granular layer (GL) (Fig. 1.8A). The zebrafish cerebellum contains different 
types of neurons, including PCs, ECs, granule cells (GCs), Golgi cells and stellate cells (Fig. 
1.8B). The climbing fibers (CFs) are afferent fibers which project from the neurons in the 
inferior olivary nucleus and form synapses with PCs. The mossy fibers (MFs) are the other 
type of afferent fibers to the cerebellum which project from the neurons in the precerebellar 
nuclei and form synapses with GCs. The signals from the MFs are transported by the axons of 
GCs which are called parallel fibers (PFs) to the PC dendrites. In addition, stellate cells send 
inhibitory signals to the PC dendrites. All of these information are integrated in PCs and sent 
through their axons to ECs which send the output signals outside the cerebellum (Bae et al. 





Figure 1.8 The zebrafish cerebellum 
(A) Schematic Illustration of the cerebellar sagittal section. Va, CCe, LCa, ML, 
PCL, GL, TeO, CC, MON and IO stand for valvula cerebelli, corpus cerebelli, 
lobus caudalis cerebelli, molecular layer, Purkinje cell layer, and granular 
layer, tectum opticum, crista cerebellaris, medial octavolateralis nucleus and 
inferior olivary nucleus, respectively. Anterior is to the left. 
(B) Schematic Illustration of the cerebellar neural circuitry. 







1.4 Is zebrafish a promising candidate for SCA1 disease 
modeling? 
There is a high degree of similarity between zebrafish and mammals in terms of genetics, 
physiology and anatomy (Zon and Peterson 2005). Recently, zebrafish represents an emerging 
tool for modeling complex brain diseases (Meshalkina et al. 2017) and it is speedily becoming 
a widespread model organism in neuropharmacology (Kalueff et al. 2014). Genetic methods 
in zebrafish have been rapidly expanding in the past years making zebrafish genetically 
tractable and allowing for the easy generation of transient and stable transgenic animals. Due 
to the transparency of the embryos, using zebrafish as model organism offers the unique 
possibility to observe cellular and subcellular mechanisms underlying differentiation and 
degeneration of the cells in a living vertebrate model organism (Lieschke and Currie 2007). 
The high fecundity of zebrafish as well as the small size and fast development of their 
embryos could be useful for in vivo drug screening and evaluation (Zon and Peterson 2005). 
Since the cerebellum is highly conserved between zebrafish and human in genetics, structure 
and function, zebrafish offers a powerful model to study the cerebellar neuronal networks in 
vivo. The zebrafish cerebellum is unfolded and directly located underneath the skin of dorsal 
hindbrain which makes it optimal for in vivo cellular and subcellular studies (Matsui et al. 
2014). Advances in imaging technologies also allow for investigating detailed cellular and 
molecular processes in the zebrafish brain (Schramm et al. 2021). In addition, Namikawa and 
colleagues (2019) could recently identify a compact enhancer element that induces expression 
specifically in zebrafish cerebellar PCs, the most vulnerable cells affected by SCA1. This 
compact regulatory element of 258 base pairs (bp), cpce (ca8 promoter-derived PC-specific 
enhancer element), was isolated from upstream of the zebrafish gene carbonic anhydrase VIII 
(ca8) and successfully used to induce green fluorescent protein (GFP) expression in PCs of a 
stable transgenic zebrafish strain. Such expression is observed at 4 dpf with the early 
differentiation of PCs (Fig. 1.9A) and lasts until adulthood (Fig. 1.9B) (Namikawa et al. 
2019b). This tool made zebrafish PCs accessible for exclusive expression of desired genes 








Figure 1.9 Expression pattern of PC-specific GFP under control of the regulatory element 
cpce (ca8 promoter-derived PC-specific enhancer element) in Tg(en.cpce-E1B:GFP)bz13 
stable transgenic strain  
(A) The green fluorescence reveals the PC-specific expression of GFP in 4 dpf larval 
zebrafish. 
(B) Immunohistochemical staining against GFP (green) counterstained by DAPI (blue) 
in a sagittal brain section reveals the PC-specific expression of GFP in adult 
zebrafish. 
Modified from (Namikawa et al. 2019a). 
 
Furthermore, the SCA1 protein Atx1 as well as the other cellular proteins known to be 
involved in the SCA1 toxicity, such as CIC and RBM17, are conserved in zebrafish (Woods 
et al. 2005; Carlson et al. 2009b; Chen et al. 2014; Mehjabin et al. 2019). This suggests that 
the pathological pathways of SCA1 can be recapitulated in zebrafish. The Atx1 gene was 
investigated in zebrafish and two homologs, Atx1a and Atx1b, were identified. These 
zebrafish homologs encode for proteins expressed in the zebrafish cerebellum with conserved 
domains essential for SCA1 pathology (Carlson et al. 2009b; Vauti et al. 2020) (Fig. 1.10). 
Carlson and colleagues (2009) recommended that modeling of SCA1 in zebrafish can result in 
a useful model for studying the pathology of SCA1 as well as screening of the toxicity and 
bioactivity of many potential drugs before testing on large animal models. Therefore, 
establishment of a SCA1 zebrafish model promises to be rewarding for characterizing disease 







Figure 1.10 Comparison of the Ataxin-1 protein between human and zebrafish 
Zebrafish expresses two Ataxin-1 homologs which show conservation with human 
Ataxin-1. The percentage shown on zebrafish homologs is the percentage of amino-
acid identity with human Ataxin-1. There is high identity in the AXH domain (in 
black), the functional domain in the interactions of the Ataxin-1 protein with the 
most of its interactors. The total number of amino acids in each protein is shown 















1.5 The aim of this study 
The aim of this study is to establish a stable transgenic zebrafish model for the 
neurodegenerative polyQ disease SCA1. Thus far, SCA1 has been in vivo-modelled in mouse 
and fruit fly, and these models have provided a deep understanding about the molecular 
mechanisms and cellular processes underlying mutant Atx1-induced cytotoxicity. However, 
such pathological mechanisms are not fully understood (Rousseaux et al. 2018; Lee et al. 
2021), and there is no treatment against the SCA1 disease yet (Bondar et al. 2018; Nitschke et 
al. 2021). Therefore, it would definitely be of advantage if an additional model could be 
available allowing for monitoring and bioimaging the SCA1-induced pathological progression 
in PCs in vivo. 
The accessibility of SCA1-affected PCs at zebrafish larval stages by in vivo bioimaging, the 
small size of these larvae and their aquatic environment well-suited for pharmacological 
treatments and behavioral analysis, as well as the previously-identified PC-specific enhancer 
element in zebrafish (Namikawa et al. 2019b) are important advantages. Therefore, the 
current study aims at inducing PC neurodegeneration in zebrafish by overexpressing the 
human pathogenic Atx1 protein using the characterized enhancer to generate the first 
transgenic zebrafish model for SCA1. This model will allow for further complementing the 
previously-described animal models for a deeper understanding of the cellular and molecular 
mechanisms of SCA1 pathology in addition to an in vivo evaluation of promising 
neuroprotective substances against neurodegeneration. The aim of the study can be 
accomplished through the following objectives: 
1.5.1 Generation of human pathogenic Ataxin-1-expressing stable 
transgenic zebrafish strain 
It might be feasible to generate transient transgenic Atx1[82Q]-expressing zebrafish larvae to 
study the SCA1 pathological mechanisms as well as to validate the effectiveness of the 
compounds to moderate disease progression. However, the mosaic nature of transgene 
expression with varying expression levels could cause difficulty to validate the speed of 
SCA1 disease progression and further complicating the comparison of the effectiveness of 
neurodegeneration inhibiting compounds. This study therefore aims to generate a stable 




population and inherited into the next generations. In these fish, Atx1[82Q] is expressed at 
comparable levels in all PCs. 
1.5.2 Characterization of neurodegeneration of SCA1-affected 
Purkinje cells 
PC degeneration in zebrafish genetic model of SCA1 is investigated in an age-dependent 
manner in order to answer the following questions: 
 Could the human pathogenic Atx1 induce neurodegeneration of zebrafish PCs? 
 How robust is this PC neurodegeneration in zebrafish? 
 When does this neurodegeneration of PCs start in zebrafish?  
 Does this disease model show age-related progredient disturbances of the PCL in 
zebrafish reminiscent of the progredient neurodegenerative SCA1 disease in human 
patients? 
1.5.3 Assessment of physiological properties of SCA1-affected 
Purkinje cells 
Physiological properties of PCs are assessed in vivo using calcium imaging. Here, some 
important questions need to be answered: 
 Does the neuronal activity of zebrafish PCs get affected by overexpression of the 
human pathogenic Atx1[82Q]? 
 When could PCs display these functionality abnormalities?  
1.5.4 Monitoring SCA1-induced behavioral changes in SCA1 
transgenic zebrafish 
Although the anatomical organization and the function of the zebrafish cerebellum has been 
shown to be conserved (Bae et al. 2009; Matsui et al. 2014), the contribution of degenerating 
PCs to altered zebrafish behavior still remains to be investigated. This study aims to answer 
the following questions: 




 Which phase of PC neurodegeneration could induce behavioral changes in SCA1 
transgenic zebrafish? 
 Does this zebrafish disease model display age-related progressive behavioral deficits 
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2 Materials and Methods 
2.1 Materials 
In the subsequent subsections, the materials used to perform the experiments of this study are 
listed. 
2.1.1 Equipment 
Various devices were used in the different experiments. The technical equipment used in this 
study is listed in table 2.1. 
Table 2.1 Equipment 
Device Description Supplier 
Confocal laser scanning 
microscope 
LSM 880 Zeiss, Oberkochen, Germany 
Confocal laser scanning 
microscope 




M205 FA Leica Microsystems, Wetzlar, 
Germany 
Stereomicroscope S8 APO Leica Microsystems, Wetzlar, 
Germany 
Centrifuge 5415C Eppendorf, Hamburg, Germany 
Thermoshaker Thermoshaker 5436 Eppendorf, Hamburg, Germany 
Vortex REAX2000 Heidolph, Schwabach, 
Germany 
Rotator LD-79 Labinco BV, Breda, the 
Netherlands 
Incubator B 6120 Heraeus, Hanau, Germany 
Electrophoresis power 
Supply 
EC105 Thermo Fisher Scientific, 
Schwerte, Germany 





40-0708 peQlab Biotechnologie GmbH, 
Erlangen, Germany 
Spectrophotometer DeNovix DS-11+ Biozym, Hessisch Oldendorf, 
Germany 
Vertical pipette puller Dki 700C David Kopf Instruments, 
Tujunga, CA, USA 
Microinjector FemtoJet 4x Eppendorf, Hamburg, Germany 
Micromanipulator MN-151 Narishige scientific instrument 
lab., Tokyo, Japan 
Pipetboy ACU 2 Integra Biosciences, Biebertal, 
Germany 
Cryostat CM3050 S Leica Microsystems, Wetzlar, 
Germany 
Vibratome VT1000 S Leica Microsystems, Wetzlar, 
Germany 
 
2.1.2 Software for data acquisition and analysis 
In this study, there are different types of data. In the subsequent sections, the software 
programs that were used for acquisition, processing and analysis of such data are listed. 
2.1.2.1 Software for imaging 
 ZEISS ZEN (black edition), associated with the ZEISS LSM 880 confocal microscope, 
Zeiss, Oberkochen, Germany. 
 LAS X, Leica Microsystems, Wetzlar, Germany. 
 NIS-Elements D 5.11.01, Nikon, Düsseldorf, Germany. 
2.1.2.2 Software for image processing, analysis and visualization 
 ZEISS ZEN (black edition), associated with ZEISS LSM 880 confocal microscope, 
Zeiss, Oberkochen, Germany. 
 ZEISS ZEN 3.0 (blue edition), Zeiss, Oberkochen, Germany. 
 LAS X, Leica Microsystems, Wetzlar, Germany. 
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 ImageJ 1.52c, National Institutes of Health (NIH), Bethesda, MD, USA. 
 Volocity 6.3, PerkinElmer, Waltham, MA, USA. 
 Imaris 9.6.0, Oxford instruments, Zurich, Switzerland. 
 Adobe Illustrator CC 2018, Adobe, San José, CA, USA. 
2.1.2.3 Software for animal behavior tracking and analysis 
 EthoVision XT 12, Noldus, Wageningen, the Netherlands. 
 VLC media player 3.0.11 Vetinari, VideoLAN, Paris, France. 
2.1.2.4 Software for data analysis and visualization 
 GraphPad Prism 9, Insightful Science, San Diego, CA, USA. 
 SnapGene 5, Insightful Science, San Diego, CA, USA. 
 Microsoft Office 2016, Microsoft, Redmond, WA, USA. 
2.1.3 Bacterial strain for transformation 
Escherichia coli bacterial strain XL1-Blue (Bullock et al. 1987) with ampicillin selection was 
used as competent cells for high efficiency transformation and amplification of target plasmids 
DNA. 
2.1.4 Chemicals 
The chemicals used in this study are listed in table 2.2. 
Table 2.2 Chemicals 
Chemical Supplier 
Tricaine Sigma-Aldrich, Taufkirchen, Germany 
Mivacurium chloride
12
 Santa Cruz Biotechnology, Dallas, 
TX, USA 
Paraformaldehyde (PFA) Carl Roth, Karlsruhe, Germany 
HPLC water 
 
Carl Roth, Karlsruhe, Germany 
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6x Gel loading dye Purple New England Biolabs, Frankfurt am Main, 
Germany 
1kb DNA ladder New England Biolabs, Frankfurt am Main, 
Germany 
Phenol red solution 0.5% Sigma-Aldrich, Taufkirchen, Germany 
N-Phenylthiourea (PTU) Sigma-Aldrich, Taufkirchen, Germany 
Normal goat serum (NGS) Vector laboratories, Burlingame, CA, USA 
Triton X-100 Sigma-Aldrich, Taufkirchen, Germany 
Sodium chloride (NaCl) Sigma-Aldrich, Taufkirchen, Germany 
Magnesium sulfate (MgSO4) Carl Roth, Karlsruhe, Germany 
Dithiothreitol (DTT) 100 mM Promega, Walldorf, Germany 
RiboLock RNase Inhibitor Thermo Fisher Scientific, Schwerte, 
Germany 
Ethanol (EtOH) Sigma-Aldrich, Taufkirchen, Germany 
Methanol (MeOH) VWR International, Darmstadt, Germany 
Mayer's Hematoxylin solution Sigma-Aldrich, Taufkirchen, Germany 
Eosin solution Sigma-Aldrich, Taufkirchen, Germany 
Entellan mounting medium Sigma-Aldrich, Taufkirchen, Germany 




The enzymes used in the biotechnology methods and cloning procedures in this study are 
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Table 2.3 Enzymes 
Enzyme Supplier 
Restriction endonucleases New England Biolabs, Frankfurt am Main, 
Germany 
T4 Ligase Thermo Fisher Scientific, Schwerte, 
Germany 
Klenow New England Biolabs, Frankfurt am Main, 
Germany 
Phusion DNA Polymerase Thermo Fisher Scientific, Schwerte, 
Germany 
DNase I (RNase-free) Thermo Fisher Scientific, Schwerte, 
Germany 
T3 RNA Polymerase Promega, Walldorf, Germany 
T7 RNA Polymerase Promega, Walldorf, Germany 
Sp6 RNA Polymerase Promega, Walldorf, Germany 
 
2.1.6 Antibodies 
The antibodies used for immunohistochemistry in this study are listed in table 2.4. 
Table 2.4 Antibodies 
Antibody Host Antigen Dilution Supplier ID 
Anti-HA  Rat HA-tag 1:1000 Chromotek, 
Planegg, Germany 
#7C9 
Anti-ZebrinII  Mouse Aldolase C 1:500 Prof. R. Hawkes 
(Brochu et al. 1990) 
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2.1.7 Solutions and media 
The standard solutions for zebrafish use and care were modified from the previous studies 
(Kimmel et al. 1995; Matthews et al. 2002). Moreover, the standard laboratory buffers were 
prepared as described in the previous studies (Sambrook and Russell 2001). 
2.1.7.1 Fish-related solutions 
The fish-related solutions used in this study are listed in table 2.5.  
Table 2.5 Fish-related solutions 
Solution Ingredients 
30% Danieau medium 0.12 mM MgSO4 
0.18 mM Ca(NO3)2 
0.21 mM KCl 
1.5 mM HEPES (pH 7.2) 
17.4 mM NaCl 
The medium was filled up to 1 liter with 
ddH2O 
0.3% N-Phenylthiourea (PTU) stock 
solution 
1.2 g PTU 
400 ml 30% Danieau medium 
Anti-pigmentation medium: 
0.003% PTU/Danieau medium 
10 ml 0.3% PTU 
990 ml 30% Danieau medium 
Egg water 0.04 g/l Sea salt in ddH2O 
Tris buffer (1 M, pH 9.5) 121.14 g Tris(hydroxymethyl)aminomethane 
was filled up to 1 liter with ddH2O 
The pH was adjusted to 9.5 
0.2% Tricaine stock solution 200 mg Tricaine powder 
97.9 ml ddH2O 
The pH was adjusted to ~7 with Tris (1 M, 
pH 9.5) 
0.04% Tricaine for anaesthesia 0.04% Tricaine in 30% Danieau medium 
(v/v) 





10 mM Na2HPO4 
2 mM KH2PO4 
137 mM NaCl 
2.7 mM KCl 
The pH was adjusted to 7.4 
 
2.1.7.2 Cloning solutions 
The cloning solutions used in this study are listed in table 2.6. 





10 g Bacto-tryptone 
5 g Yeast extract 
10 g NaCl 
1 Liter ddH2O 
The pH was adjusted to 7.4 
LB-Agar 10 g Bacto-tryptone 
5 g Yeast Extract 
10 g NaCl 
15 g Agar 
1 Liter ddH2O 
 
2.1.7.3 Histological-staining buffers 
The solutions used for Hematoxylin-Eosin staining and immunohistochemical staining in this 
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Table 2.7 Fixation and staining buffers 
Solution Ingredients 
20% Triton stock solution 10 ml Triton X-100 
The detergent solution was filled up to 50 
ml with ddH2O 
PBST (Phosphate-buffered saline with 
Triton) 
0.3% Triton in 1x Phosphate-buffered 
saline (PBS) (v/v) 
4% PFA 40 g Paraformaldehyde (PFA) 
1 Liter ddH2O 
The pH was adjusted to 7.2 
Fixation buffer 4% PFA in PBST (v/v) 
PBST DMSO 1% Dimethyl Sulfoxide (DMSO) in PBST 
(v/v) 
NGS Blocking buffer 10% NGS (Normal Goat Serum) in PBST 
DMSO (v/v) 
 
2.1.8 Kits and reagents for high-affinity purification  
The kits used in this study for high-affinity extraction and purification of nucleic acids are 
listed in table 2.8. 
Table 2.8 Purification kits 
Kit Supplier 
FastGene Gel/PCR Extraction Kit NIPPON Genetics EUROPE, Düren, Germany 
RNeasy Mini Kit 250 QIAGEN, Hilden, Germany 
RNeasy Midi Kit 50 QIAGEN, Hilden, Germany 
 
2.1.9 Oligonucleotides 
It was important after each cloning step to confirm by sequencing that the number of CAG 
repeats in both non-pathogenic Atx1[30Q] and mutant Atx1[82Q] human alleles were kept the 
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same during the cloning procedures in the successive cloning steps. In addition, it was 
important before injection to confirm by sequencing that Atx1[30Q] and Atx1[82Q] were N-
terminally fused to an HA-tag for immunohistochemical detection. The Oligonucleotides used 
for these purposes are listed in table 2.9. 
Table 2.9 Oligonucleotides 
Oligonucleotide Sequence Stock 
no. 
Human Atx1, upstream PolyQ, for 
for sequencing of the polyQ sequence 
in human Atx1  
5' TCCCAGCTGGAGGCCTATTC 3' #3472 
Human Atx1, downstream PolyQ, rev 
for sequencing of the polyQ sequence 
in human Atx1 
5' GTATTGCATGACGACCTGGGA 3' #3473 
Human Atx1, N-terminus, rev 
for sequencing of the  HA-tag 
sequence 
5' TCGGAGGACCGGCTGGTGGC 3' #1674 
 
2.1.10 Plasmid vectors for microinjection 
pA-4xmir181aT-GAPmScarlet-E1b-8×ca8-E1b-4xmir181aT-pA (Stock no. #5158) 
This vector drives overexpression of the membrane-targeted red fluorescent reporter 
GAPmScarlet in the cell membranes of zebrafish Purkinje neurons. GAP is a membrane-
targeting signal isolated from the amino terminus of the zebrafish neuronal protein Growth 
Associated Protein 43 (GAP-43) ( (Zuber et al. 1989). mScarlet is a bright red fluorescent 
protein that demonstrates high performance in cellular microscopy (Bindels et al. 2017). The 
PC-specific expression occurs under control of the 258-bp enhancer element cpce isolated 
from upstream of the zebrafish gene ca8. Adding 2x4 copies of the enhancer element cpce in 
opposite orientation and flanking it on both sides with E1b basal promoter, multiple cloning 
site, 4 copies of miRNA181aT (mir181aT) target fragment and SV40 polyadenine (pA) 
sequence mediates robust PC-specific expression of two different transgene cassettes 
(Namikawa et al. 2019b). However, there is only one transgene cassette, GAPmScarlet, 
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expressed in this vector. In addition, the both sides are flanked by Tol1 transposon recognition 
sites (Koga et al. 2008). 
pA-4xmir181aT-GAPmScarlet-E1b-8×ca8-E1b-HA:Atx1[30Q]-4xmir181aT-pA (Stock no. 
#3417) 
This vector drives overexpression of the human non-pathogenic allele Atx1[30Q] in the nuclei 
of zebrafish Purkinje neurons in addition to the membrane-targeted red fluorescent reporter 
GAPmScarlet in the cell membranes of Purkinje neurons. The human non-pathogenic allele 
Atx1[30Q] is N-terminally tagged with an HA-tag for the staining purposes. The PC-specific 
expression occurs under control of the 258-bp enhancer element cpce isolated from upstream 
of the zebrafish gene ca8. Adding 2x4 copies of the enhancer element cpce in opposite 
orientation and flanking it on both sides with E1b basal promoter, multiple cloning site, 4 
copies of mir181aT target fragment and SV40 pA sequence mediates robust PC-specific 
expression of two different transgene cassettes, GAPmScarlet and Atx1[30Q] (Namikawa et 
al. 2019b). In addition, the both sides are flanked by Tol1 transposon recognition sites (Koga 
et al. 2008). 
pA-4xmir181aT-GAPmScarlet-E1b-8×ca8-E1b-HA:Atx1[82Q]-4xmir181aT-pA (Stock no. 
#5187) 
This vector drives the overexpression of human pathogenic allele Atx1[82Q] in the nuclei of 
zebrafish Purkinje neurons in addition to the membrane-targeted red fluorescent reporter 
GAPmScarlet in the cell membranes of Purkinje neurons. The human pathogenic allele 
Atx1[82Q] is N-terminally tagged with an HA-tag for the staining purposes. The PC-specific 
expression occurs under control of the 258-bp enhancer element cpce isolated from upstream 
of the zebrafish gene ca8. Adding 2x4 copies of the enhancer element cpce in opposite 
orientation and flanking it on both sides with E1b basal promoter, multiple cloning site, 4 
copies of mir181aT target fragment and SV40 pA sequence mediates robust PC-specific 
expression of two different transgene cassettes, GAPmScarlet and Atx1[82Q] (Namikawa et 
al. 2019b). In addition, the both sides are flanked by Tol1 transposon recognition sites (Koga 
et al. 2008). 
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2.1.11 Zebrafish strains 
2.1.11.1 Wild-type zebrafish 
Zebrafish of the brass strain, a reduced melanin mutant strain (Gross and Perkins 2008), was 
used as wild-type fish in this study. This strain has less pigmentation on the body surface 
caused by melanocyte deficiency, which affects the melanin synthesis. Therefore, embryos and 
early larvae of this line are easily-accessible for observing the fluorescent proteins by 
fluorescence microscopy. 
2.1.11.2 Transgenic lines 
The following stable transgenic lines were generated by microinjection of the desired DNA 
construct into the cytoplasm of one cell stage embryos of the brass strain: 
 Tg: GAPmScarlet-8×ca8 
This transgenic line was generated by microinjection of a DNA construct expressing the 
membrane-targeted red fluorescent reporter GAPmScarlet under control of the PC-specific 
enhancer element cpce isolated from upstream of the zebrafish gene ca8 (Namikawa et al. 
2019b). GAP is a membrane-targeting signal isolated from the amino terminus of the neuronal 
protein Growth Associated Protein 43 (GAP-43) ( (Zuber et al. 1989). 
This line was generated to overexpress the membrane red fluorescent protein GAPmScarlet in 
specific neuronal cell type (PCs) to monitor the morphology of Purkinje neurons and to 
quantify the area of their population at different ages. The stock number of plasmid vector 
injected to generate this transgenic line is #5158. 
Tg: GAPmScarlet-8×ca8-HA:Atx1[30Q] 
This transgenic line was generated by microinjection of a bidirectional DNA construct 
expressing the human non-pathogenic allele Atx1[30Q] together with the membrane-targeted 
red fluorescent reporter GAPmScarlet under control of the PC-specific enhancer element cpce 
isolated from upstream of the zebrafish gene ca8 (Namikawa et al. 2019b). The HA-tag was 
fused to the N-terminus of the Atx1[30Q] protein. 
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This line was generated to overexpress the human non-pathogenic full-length gene Atx1[30Q] 
in a specific neuronal cell type (PCs) that is the most vulnerable one affected by the SCA1 
disease. In addition, the red fluorescent protein GAPmScarlet was coexpressed to monitor the 
morphology of Purkinje neurons and to quantify the area of their population at different ages. 
The HA-tag was used for the immunostaining of the protein. The stock number of plasmid 
vector injected to generate this transgenic line is #3417. 
Tg: GAPmScarlet-8×ca8-HA:Atx1[82Q] 
This transgenic line was generated by microinjection of a bidirectional DNA construct 
expressing the human SCA1-causing pathogenic allele Atx1[82Q] together with the 
membrane-targeted red fluorescent reporter GAPmScarlet under control of the PC-specific 
enhancer element cpce isolated from upstream of the zebrafish gene ca8 (Namikawa et al. 
2019b). The HA-tag was fused to the N-terminus of the Atx1[82Q] protein. 
This line was generated to overexpress the human mutant full-length gene Atx1[82Q] in a 
specific neuronal cell type (PCs) that is the most vulnerable population affected by the SCA1 
disease. In addition, a membrane red fluorescent protein GAPmScarlet was coexpressed to 
monitor the morphology of Purkinje neurons and to quantify the area of their population at 
different ages. The HA-tag was used for the immunostaining of the protein. The stock number 




The zebrafish of this transgenic strain express a green fluorescent protein exclusively in PCs 
under control of the ca8 promoter-derived PC-specific enhancer element cpce (Namikawa et 
al. 2019b; Chang et al. 2020). This transgenic line was crossed with the control, Atx1[30Q] 
and Atx1[82Q] transgenic lines to establish double transgenic zebrafish expressing the 
reporter protein GFP together with GAPmScarlet only, Atx1[30Q] or Atx1[82Q] specifically 
in PCs. This experiment was used to reveal whether the transgene expression in the control, 











 are expressing the genetically-encoded Ca
2+
 indicator 
GCaMP6s, with the calcium-binding protein calmodulin (CaM) and the reporter protein GFP 
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(Chen et al. 2013), specifically in PCs under control of Gal4/UAS system mediated by the 
Gal4 variant, KALNFB (Namikawa et al. 2019b). This transgenic line was crossed with the 
control, Atx1[30Q] and Atx1[82Q] transgenic lines to establish triple transgenic zebrafish 
expressing Ca
2+
 indicator GCaMP6s together with GAPmScarlet only, Atx1[30Q] or 
Atx1[82Q] specifically in PCs. This experiment was used to compare the physiological 





















2.2.1 Biotechnology methods and cloning procedures 
Three plasmids DNA were constructed expressing the membrane-targeted red fluorescent 
reporter GAPmScarlet only (control), or together with the human non-pathogenic allele 
Atx1[30Q] or the human SCA1-causing mutant Atx1[82Q] in bidirectional vectors. GAP is a 
membrane-targeting signal isolated from the N-terminus of the zebrafish neuronal protein 
Growth Associated Protein 43 ( (Zuber et al. 1989). mScarlet is a bright red fluorescent 
protein which shows great performance in cellular imaging (Bindels et al. 2017). Both human 
alleles Atx1[30Q] and Atx1[82Q] were N-terminally fused to an HA-tag for 
immunohistochemical detection. The bidirectional expression occurs under control of the 258-
bp regulatory element cpce (ca8 promoter-derived PC-specific enhancer element). This small 
genomic element is isolated from upstream of the zebrafish gene carbonic anhydrase VIII 
(ca8) and is able to specifically drive expression in zebrafish PCs starting at their time point 
of differentiation at 2.5 dpf (Namikawa et al. 2019b). Adding 2x4 copies of the enhancer 
element cpce in opposite orientation and flanking it on both sides with E1b basal promoter 
(Huang et al. 2006), multiple cloning site, 4 copies of miRNA181aT target fragment and SV40 
polyadenine sequence mediates robust PC-specific expression of two different transgene 
cassettes (Namikawa et al. 2019b). In addition, the both sides are flanked by Tol1 transposon 
recognition sites (Koga et al. 2008). The biotechnology methods and cloning procedures for 
constructing these plasmids DNA were as follows: 
2.2.1.1 DNA digestion 
Digestion solutions were prepared according to the following protocol: 
Vector solution: 1 μl of the plasmid DNA (1 μg/μl) + 1 μl per restriction enzyme + 3 μl 10x 
buffer + HPLC water to a total volume of 30 μl. 
Insert solution: 2 μl of the plasmid DNA (1 μg/μl) + 1 μl per restriction enzyme + 3 μl 10x 
buffer + HPLC water to a total volume of 30 μl. 
Both solutions were incubated at 37 °C for at least 1 hour. 
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The solutions were electrophoresed on 1% agarose/TAE gel and stained with ethidium 
bromide for at least 10 minutes. The required bands were cut out from the gel and transferred 
into a 1.5-ml reaction tube.  
2.2.1.2 DNA Purification 
Vector and insert DNA were purified out of the gel using gel extraction kit according to the 
following protocol: 
500 µl PN buffer was added to each gel slice in both reaction tubes. 
Gel was dissolved on a thermoshaker at 55 °C and maximum speed for at least 5 minutes. 
The mixture was then added (max. 800 µl) onto a purification column (FastGene Gel/PCR 
Extraction Kit, NIPPON Genetics EUROPE). 
It was centrifuged at 8,000 rpm for 10 ˗ 15 seconds. 
Flow-through was thrown away. 
600 µl PE buffer was added onto the column. 
The column was afterwards centrifuged at 8,000 rpm for 10 ˗ 15 seconds. 
Subsequently, it was placed in a new collection tube. 
The column was dried by centrifugation at maximum speed for 2.5 minutes. 
It was placed in a new 1.5-ml reaction tube. 
25 µl sterile water was pipetted directly to the column membrane (without touching it). 
It was then centrifuged at maximum speed for 1 minute. 
2.2.1.3 DNA Ligation 
Digested and purified DNA of both vector and insert was used for ligation according to the 
following protocol: 
2 µl vector solution + 6 µl insert vector solution were mixed. 
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1.5 µl T4-ligase buffer was added to the mixture. 
0.5 µl T4-ligase was added. 
5 µl HPLC water was also added. 
The ligation mix was then incubated at room temperature for 20 minutes. 
It was cooled down on ice before starting the transformation. 
2.2.1.4 Plasmid transformation 
Transformation is the process by which the competent bacterial cells uptake and express the 
exogenous plasmid DNA using the following protocol: 
Competent bacteria which usually kept at -80 °C were thawed on ice. 
50 µl of bacterial solution was added to the ligation mix and they were mixed by pipetting. 
The mixture was incubated on ice for 15 - 30 minutes. 
It was heat shocked at 42 °C (water bath) for 45 seconds to induce bacterial uptake of the 
plasmid DNA. 
It was then cooled down on ice for 2 - 3 minutes. 
300 µl Luria Bertani (LB) medium (without any antibiotic) was added. 
The mixture was incubated on a thermoshaker at 37 °C and 900 - 1000 rpm for 15 minutes to 
1 hour. 
It was afterwards centrifuged for 1 minute at maximum speed. 
300 µl of the supernatant were thrown away for condensing the bacteria. 
The bacterial pellet was resuspended in the remaining supernatant and spread well onto a 
selection agar plate containing the right antibiotic. 
The plate was incubated overnight at 37 °C until the suitable size of bacterial colonies 
appeared. 
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2.2.1.5 Small-scale DNA preparation from bacteria (Mini Prep) 
For analysing the bacterial colonies prepared with cloning procedures, isolation of small-scale 
plasmid DNA from bacteria was performed according to the following protocol: 
Some selected bacterial colonies were inoculated separately in 2 ml LB-medium containing 
the selective antibiotic. 
They were incubated in a shaker overnight (~ 16 hours) at 37 °C and 180 rpm. 
Each bacterial solution was transferred into a 1.5-ml reaction tube. 
It was centrifuged at maximum speed for 2.5 minutes to form a bacterial pellet. 
The supernatant was thrown away by using vacuum pump then a DNA isolation and 
purification kit (RNeasy Mini Kit 250, QIAGEN) was used in the next steps. 
150 µl RNase containing resuspension buffer was used to resuspend the pellet by vortexing. 
150 µl alkaline lysis buffer was added and mixed by inverting the tube. 
150 µl neutralization buffer was applied and mixed by inverting the tube to coagulate 
denatured proteins and precipitate the bacterial debris. 
The mixture was afterwards centrifuged at maximum speed for 5 minutes. 
Subsequently, the supernatant was transferred into a new 1.5-ml reaction tube. 
100% ethanol was added to 1.5 ml. 
The mixture was vortexed well and centrifuged at maximum speed for 5 minutes. 
The supernatant was discarded and the DNA pellet was dried in room temperature. 
The DNA pellet was resuspended in 50 µl ddH2O. 
For selecting the positive bacterial colonies, 2 µl of each DNA solution were mixed with 0.25 
µl per restriction enzyme, 1.5 µl 10x buffer and ddH2O to 15 µl, incubated at 37 °C for at 
least 30 minutes and checked for the target vector and insert bands on 1% agarose/TAE gel 
(electrophoresis). 
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2.2.1.6 Large-scale DNA preparation from bacteria (Midi Prep) 
In order to get a large amount of the required plasmid DNA, the target DNA from a positive 
bacterial colony was amplified, isolated and purified according to the following protocol: 
The selected bacterial colony was cultured in 100 ml LB-medium containing the selective 
antibiotic. 
It was incubated in a shaker overnight (~ 16 hours) at 37 °C and 180 rpm. 
The bacterial solution was transferred into two 50-ml Falcon tubes. 
The solution was centrifuged at 4 °C and 4500 rpm for 10 minutes to form a bacterial pellet. 
The supernatant was discarded and a DNA isolation and purification kit (RNeasy Midi Kit 50, 
QIAGEN) was used in the next steps. 
8 ml RNase containing resuspension buffer was used to resuspend the pellet by vortexing. 
8 ml alkaline lysis buffer was added and mixed by inverting the tube. 
The solution was incubated at room temperature for 3 minutes. 
During lysis buffer treatment, the purification column was equilibrated by washing with 12 ml 
equilibration buffer. 
8 ml neutralization buffer was applied and mixed well by inverting the tube to coagulate 
denatured proteins and precipitate the bacterial debris. 
The mixture was loaded onto the column. 
After the whole cell lysate ran through, the column was washed with 5 ml equilibration 
buffer. 
Subsequently, the column’s filter was removed and the column’s membrane was washed with 
8 ml washing buffer. 
DNA was eluted from the membrane by 5 ml elution buffer and collected in a 50-ml Falcon 
tube. 
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3.5 ml isopropanol was added and mixed by vortexing. 
The mixture was centrifuged at 4 °C and 5000 rpm for 30 minutes and the supernatant was 
then discarded. 
The DNA pellet was transferred using 500 µl 70% ethanol into a 1.5-ml reaction tube and 
centrifuged at maximum speed for 5 minutes. 
The supernatant was completely thrown away with a pipette and the pellet was dried in room 
temperature for 5 minutes. 
The DNA pellet containing the target plasmid DNA was resuspended well in 200 µl HPLC 
water. 
The concentration of DNA was measured by a spectrophotometer (DeNovix DS-11+, 
Biozym). 
The DNA solution was diluted with HPLC water to the concentration of 1 µg/µl and stored in 
-20 °C. 
2.2.1.7 Tol1 mRNA synthesis 
mRNA encoding for the transposon Tol1 was prepared according to the following protocol: 
12 µg plasmid DNA template for Tol1 mRNA synthesis was digested with 2.5 µl appropriate 
restriction enzyme for 2 hours at 37 °C in HPLC water added to a total volume of 30 μl. 
1 µl linearized plasmid DNA solution was checked by gel electrophoresis to confirm that 
DNA was completely restricted. 
DNA was purified with a purification column (FastGene Gel/PCR Extraction Kit, NIPPON 
Genetics EUROPE) and eluted by 30 µl RNase-free water in a special RNase-free tube. 
The concentration of DNA was measured by a spectrophotometer (DeNovix DS-11+, 
Biozym). 
The mixture of mRNA synthesis reaction was then prepared in a special RNase-free tube at -
20 °C: 
Linearized plasmid DNA (1 µg) 
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10x transcription buffer (Roche) (5 µl) 
NTP/Cap mixture (5 µl) 
RiboLock RNase Inhibitor (Thermo Fisher Scientific) (2 µl) 
Appropriate RNA polymerase (1.5 µl) 
RNase-free water (up to 50 µl) 
This mixture was incubated for 2 hours at 37 °C and 1.5 µl RNase-free DNase I (Roche) was 
then added to the mixture and the mixture was further incubated for 15 minutes at 37 °C. The 
synthesized mRNA was purified and eluted by 50 µl RNase-free water in a special RNase-
free tube. 
The concentration of mRNA was measured by a spectrophotometer (DeNovix DS-11+, 
Biozym) and diluted to 250 ng/µl. The solution was stored at -20 °C in a special RNase-free 
tube. 
2.2.2 Zebrafish husbandry and maintenance 
Zebrafish of the brass strain, a reduced melanin mutant strain (Gross and Perkins 2008), were 
used for performing the experiments of this study. The establishment of stable transgenic 
strains, the experimental procedures and the animal numbers were approved by 
“Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit”. The 
animal protocol’s approval number is 33.19-42502-04-18/3013. Zebrafish maintenance and 
experiments were carefully performed in compliance with European accepted standards and 
German legislation (Directive 2010/63/EU, license AZ 325.1.53/56.1-TUBS) and according to 
the legal animal welfare requirements (Aleström et al. 2019). The fish were kept in an 
aquarium which is connected to a filtering system to ensure a high water quality. The 
light/dark cycle in the fish facility was set to 14 hours light and 10 hours darkness and the 
temperature was maintained at 28 °C. Mature fish were crossed in one-liter cages containing a 
fish pair overnight and the obtained embryos were collected in the following morning in petri 
dishes containing egg water and kept in a 28-°C incubator. After a few hours, the dead 
embryos were removed and the egg water was changed with 30% Danieau medium which was 
being changed daily. At 6 dpf, the larvae were transferred into the fish facility. For live 
imaging experiments and whole-mount immunohistochemistry at larval stages, the Danieau 
medium was supplemented with 0.003% PTU starting from 0.5 dpf to suppress pigmentation. 
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2.2.3 Microinjection of nucleic acids 
Three injection solutions were prepared in order to generate three transgenic strains. Each 
solution consisted of the desired circular plasmid DNA at a concentration of 25 ng/µl, mRNA 
encoding the transposon Tol1 at a concentration of 25 ng/μl and phenol red at a concentration 
of 0.05% (1:10 of a 0.5% stock solution). The phenol red was used as a color marker to 
distinguish injected embryos from uninjected ones. The injection solution was freshly prepared 
for each injection experiment. In order to establish each transgenic strain, microinjection of the 
relevant prepared solution was performed into the cytoplasm of the one cell stage embryos. A 
glass microcapillary was pulled with a vertical pipette puller (Dki 700C) to be used as a sharp-
tipped injection needle. Few microliters of the solution were filled into the needle which was 
then fixed on a micromanipulator (MN-151). The embryos were sorted in a Petri dish inside 
grooves of 1.5% solidified agarose gel. They were fixed in an orientation where the cell is at 
the top and the yolk is at the bottom. After that, the injection was performed under a 
stereomicroscope (Leica S8 APO) using the micromanipulator (MN-151). The injected 
embryos were transferred into a 28-°C incubator. 
2.2.4 Screening and generation of zebrafish stable 
transgenic strains 
In order to obtain stable transgenic zebrafish of the F2 generation, which propagate PC-
specific mScarlet, Atx1[30Q] or Atx1[82Q] expression in a Mendelian manner, the injected 
larvae were checked under a fluorescence stereomicroscope (Leica M205 FA) at 4 dpf after 
the early PC differentiation. The positive carriers which showed red fluorescence in PCs were 
collected and moved to the fish facility at 6 dpf in order to be raised as a P0 generation. After 
3 months, the young adults were screened by crossing with wild-type fish and the offspring 
was checked for red fluorescence in PCs at 4 dpf. The carrier larvae were raised to obtain adult 
F1 generation fish. Afterwards, these adult fish were crossed with wild-type fish to get, raise 
and analyze F2 generation carriers. 
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2.2.5 Whole-mount immunohistochemistry    
In order to detect the human Atx1 protein in zebrafish PCs, whole-mount 
immunohistochemistry on 4 dpf larval zebrafish was performed according to the following 
protocol modified from a previous report (Kani et al. 2010): 
10-20 carrier larvae from each transgenic line were sedated in 0.05% Tricaine for 10 minutes 
in a 2-ml tube. The medium was then completely removed and the larvae were fixed with 1 
ml cold 4% PFA/PBST in the same tube. The tube was shaken on a shaker for 3 hours at 4 °C. 
The larvae were washed with 1 ml PBST for 10 minutes. They were incubated in 1 ml cold 
acetone for 15 minutes at -20 °C and then washed once with 1 ml PBST and twice with 1 ml 
PBS-DT for 10 minutes each. They were incubated in 500 µl 5% normal goat serum/PBS-DT 
for 1 hour at room temperature on a shaker (blocking). 
The larvae were incubated in 500 µl of the primary antibody solution (1
ry
 antibody 1:1000 
dilution, 1% BSA, 1% DMSO and 0.1% Triton in PBS) overnight at 4 °C on a shaker. The 
anti-HA antibody (Chromotek) was used as the primary antibody for detecting the HA-tagged 
human Atx1 protein. The larvae were then washed with 1 ml PBST six times for 10 minutes 
each. 
They were incubated in 500 µl of the secondary antibody solution (2
ry
 antibody 1:1000 
dilution, 1% BSA, 1% DMSO and 0.1% Triton in PBS) for 2 hours at room temperature on a 
shaker. The Alexa Fluor 488 anti-mouse IgG antibody (Thermo Fisher Scientific) was used as 
the secondary antibody. The larvae were then washed with 1 ml PBST six times for 10 
minutes each. 
The stained larvae were embedded in 1% low-melting agarose/PBS inside imaging chambers 
with glass bottom. The fluorescent images of PCs were obtained with a confocal laser 
scanning microscope (ZEISS LSM 880). The images for the figures were constructed from Z-
stack planes by ZEISS ZEN software (associated with ZEISS LSM 880) and processed using 
ImageJ 1.52c software. 
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2.2.6 Measuring the fish length and isolation of the brain 
Firstly, 0.04% tricaine was used as an anesthetic compound to anesthetize the fish at 40 dpf, 2 
mpf and 3 mpf. Then, each fish was cooled down on ice and afterwards the length of the body 
form the anterior tip of the jaw until the caudal indentation of the tail fin (fork length) was 
measured using a ruler. After that, the fish was decapitated and the head was transferred to a 
Petri dish with cold 1x PBS for further dissection under a stereomicroscope (Leica S8 APO). 
All the organs and tissues such as the gills and eyes were removed using two forceps until 
reaching the skull. The skull was then broken and removed carefully to not damage the brain. 
The brain was smoothly moved into cold 4% PFA/PBS and incubated overnight at 4 °C for 
fixation. In the next morning, the brain was washed with cold 1x PBS three times for 5 
minutes each. The fixed brain was then ready for imaging using laser scanning confocal 
microscopy (ZEISS LSM 880) or for sectioning, depending on the experiment. The images 
were constructed from Z-stack planes by ZEISS ZEN (black edition) software (associated with 
ZEISS LSM 880) and processed using ImageJ 1.52c software. The figures were prepared 
using Adobe Illustrator CC 2018 software. For quantification, the area of the PC region was 
measured using Volocity 6.3 software. 
2.2.7 Histology and immunostaining of the zebrafish brain 
The fixed brain of adult zebrafish was cut to 70 µm-thick sagittal sections using a vibratome 
(Leica VT1000 S) for Hematoxylin-Eosin staining or 40 µm-thick sagittal sections using a 
cryostat (Leica CM3050 S) for immunohistochemistry. In terms of Hematoxylin-Eosin 
staining, the brain was pre-embedded in 1% low-melting agarose/PBS at 37 °C for 30 minutes. 
The brain was then transferred into a special embedding mold. The agarose gel was removed 
and the brain was embedded in 3% agarose/PBS for making the block for cutting. The 
orientation of the brain was quickly adjusted after adding the 3% agarose as it solidifies very 
fast. After this adjustment, the agarose block was left to cool down to room temperature and 
the cutting was then performed at a frequency of 80 Hz in the vibratome's cutting box filled 
with 1x PBS. The 70 µm-thick cerebellar sagittal sections were mounted on a SuperFrost glass 
slide (Thermo Fisher Scientific), dried at 40 °C and stained with Hematoxylin-Eosin according 
to the following protocol: 
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The glass slide with the brain sections was rinsed in tap water for 5 minutes and then in 
Mayer's Hematoxylin solution for 8 minutes. It was shortly rinsed 3 times in tap water and 
once in freshly-prepared ethanol/HCl (200 ml absolute ethanol + 6 ml 37% HCl). 
The slide was washed under running tap water for 10 minutes and then rinsed in Eosin solution 
for 1 minute. It was rinsed shortly in 70% ethanol once, for 2 minutes in 80% ethanol twice 
and for 2 minutes in 96% ethanol twice. 
It was then rinsed twice in xylene for 2 minutes, a drop of entellan was added on the slide 
using a glass rod, and a coverslip was gently put onto the slide allowing the entellan to spread 
and cover all the brain sections. The slide was finally dried at 37 °C and the stained sections 
were visualized by stereomicroscopy (Leica S8 APO). 
In terms of immunohistochemistry, the fixed brain was incubated in 30% sucrose/PBS 
overnight at 4 °C. It was then embedded in optimal cutting temperature compound (OCT) and 
frozen at -80 °C. For cutting, the temperature of the cryostat (Leica CM3050 S) was adjusted 
at -20 °C. Cerebellar sagittal sections of 40 µm thickness were cut, mounted on a SuperFrost 
glass slide (Thermo Fisher Scientific), and immunostained according to the following 
protocol modified from a previous report (Kani et al. 2010):  
The cerebellar sections were washed with PBST for 1 hour then incubated in 5% normal goat 
serum/PBS-DT for 1 hour at room temperature (blocking). Afterwards, the sections were 
incubated in the primary antibody solution (1
ry
 antibody, 1% BSA, 1% DMSO and 0.3% 
Triton in PBS) overnight at 4 °C. The primary antibody was either the anti-HA antibody 
(1:2000 dilution) for detecting the HA-tagged human Atx1 protein, or the anti-ZebrinII 
antibody (1:500 dilution). ZebrinII is a polypeptide antigen expressed exclusively in PCs. The 
anti-ZebrinII antibody stains somata, dendrites and axons of PCs (Brochu et al. 1990).  
The sections were washed with PBST six times for 10 minutes each. They were the incubated 
in the secondary antibody solution (2
ry
 antibody 1:1000 dilution, 1% BSA, 1% DMSO and 
0.3% Triton in PBS) for 2 hours at room temperature. Alexa Fluor 488 anti-mouse IgG 
antibody was used as the secondary antibody. The sections were then washed with PBST six 
times for 10 minutes each. 
A coverslip was gently mounted on the glass slide using a mounting medium (Fluoro-Gel, 
Electron Microscopy Sciences). After drying at 37 °C, the fluorescent images of PCs were 
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obtained by laser scanning confocal microscopy (ZEISS LSM 880) and fluorescence 
stereomicroscopy (Leica M205 FA). The images for the figures were constructed from Z-









 carriers to establish triple 
transgenic zebrafish expressing the genetically-encoded Ca
2+
 indicator GCaMP6s, with the 
calcium-binding protein calmodulin (CaM) and the reporter protein GFP (Chen et al. 2013), 
specifically in PCs mediated by the Gal4 variant, KALNFB (Namikawa et al. 2019b). The 
obtained carriers, showing red fluorescence of mScarlet in the PC membrane and green 
fluorescence of GFP in the PC cytoplasm, were collected at 4 dpf under a fluorescence 
stereomicroscope (Leica M205 FA). At 6 dpf and 12 dpf, larvae with different genotpye were 
anaesthetized for one minute in 100 µl 30% Danieau medium containing Mivacurium 
chloride
12
 at a concentration of 0.5 mg/ml (Mattern et al. 2020). 
The larvae were then embedded in 2% low-melting agarose/PBS and image stack recording (5 
planes each 10µm apart) of their PCL at 1.1 Hz intervals was performed by digital light-sheet 
microscopy (Leica TCS SP8 DLS) for a duration of 333 seconds (370 frames). After the 
imaging, GCaMP6s fluorescent emission was analyzed in the third PC plane of all fish using 
ImageJ 1.52c software. The first 66 frames (60 seconds) were considered as habituation period 
and were neglected in the data analysis. The subsequent 10 frames were used as a baseline 
signal. The average of mean grey values of the baseline frames (F0) was subtracted from the 
mean grey value of each subsequent frame (F) to calculate (F-F0)/F0 for each frame. 
Moreover, the average ∆F/F0 for each fish was calculated to statistically compare the three 
fish groups. 
2.2.9 Behavioral analysis 
The novel tank diving test is a behavioral test used to characterize the exploratory behavior in 
zebrafish. The novel tank was positioned in front of a video camera for optimal recording. 
There was enough light in the tank’s background to have an appropriate contrast for accurate 
tracking and analysis. The video recording by EthoVision XT 12 software was started and the 
individual zebrafish was gently transferred with a net into the novel tank. The net was moved 
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carefully in the water allowing the fish to swim out. The tracking of the fish by the software 
started automatically after detection of the fish in the adjusted arena. The fish’s behavior in the 
tank was recorded for 6 minutes and then the fish was gently returned to its home tank (Cachat 
et al. 2010). Afterwards, the video analysis was performed automatically by the software 
according to the adjusted analysis profile with the desired parameters to be assessed. The 
assessed parameters were the percentage of time spent in the upper half of the novel tank, the 
latency until the first visit to the upper half, the whole distance traveled in the tank, the number 
of transitions to the upper half and the average, the minimum and the maximum swimming 
velocity. The results were then exported to Microsoft Excel sheets for further statistical 
analysis. 
2.2.10 Statistical analysis 
Goodness-of-fit tests, Shapiro-Wilk and Kolmogorov-Smirnov, were used to evaluate the 
deviation of data distribution from normal Gaussian distribution at a significance level of 0.05 
(Dallal and Wilkinson 1986; Royston 1995). Two-way ANOVA with post hoc Tukey’s test 
was used to evaluate the statistical significance of differences between experimental groups. 
Data are presented as mean ± SEM. p-Values which are indicated as *p < 0.05, **p < 0.01, 
***p < 0.001 and ****p < 0.0001 refer to significant differences. Experimental numbers of the 
animals per group are reported in the respective figure legends. GraphPad Prism 9 software 
was used for statistical analysis and graph plotting. 





The establishment of a SCA1 genetic model in zebrafish easily-accessible for monitoring of 
neurodegeneration and disease progression, unraveling pathological mechanisms underlying 
the disease phenotypes, as well as testing potential treatment compounds and strategies, could 
be a step towards developing therapeutic approaches. There are already some other established 
animal models, however, providing a zebrafish SCA1 model to the ataxia researchers will add 
some more advantages such as in vivo live imaging of the transparent larval carriers, cheap 
maintenance and large numbers of offspring providing sufficient specimens for various 
studies. 
3.1 Genetic modeling of SCA1 in zebrafish 
3.1.1 Genetic engineering and strategy for modeling SCA1 in 
zebrafish 
The strategy of this study for generating a zebrafish SCA1 model is to overexpress the human 
SCA1-causing gene Atx1[82Q] specifically in zebrafish PCs, the most vulnerable cells to 
SCA1 pathology in human patients. Not only the SCA1-causing gene, but also a fluorescent 
reporter, GAPmScarlet (Bindels et al. 2017), was expressed to allow for monitoring of 
affected PCs. Therefore, a bidirectional DNA vector was employed to enable the expression 
of both genes under control of the same PC-specific enhancer and consequently at the same 
spatiotemporal manner (Namikawa et al. 2019b). Furthermore, two other DNA vectors were 
constructed to establish two control fish strains. One of these control vectors expressed the 
human non-pathogenic gene Atx1[30Q] instead of Atx1[82Q] together with the fluorescent 
reporter and the other vector expressed only the fluorescent reporter (Fig. 3.1A-C). 
In order to prove that the number of CAG repeats in both non-pathogenic (30Q) and 
pathogenic mutant (82Q) alleles of human Atx1 were kept the same without alteration during 
the cloning procedures in the successive cloning steps, the constructed plasmids DNA were 
sequenced using the oligonucleotides Human Atx1, upstream PolyQ, for and Human Atx1, 
downstream PolyQ, rev for optimal sequencing of the polyQ sequence in human Atx1. The 
stock number of these oligonucleotides is 3472 and 3473, respectively. The sequencing data 




human non-pathogenic allele Atx1[30Q] revealed that the number of CAG repeats was stably 
kept at 30 without alteration during the cloning procedures. The plasmid stock number is 
5648, in which detailed cloning procedure is provided. Additionally, the sequencing of the 
DNA construct expressing the human SCA1-causing allele Atx1[82Q] revealed that the 
number of CAG repeats was stably kept at 82 without alteration during the cloning 























Figure 3.1 Genetic modeling of the human SCA1 disease in zebrafish 
Schematic drawing of expression constructs for PC-specific coexpression of the red 
fluorescent reporter protein mScarlet targeted to the cytoplasmic membrane, and 
non-pathogenic Atx1[30Q] or mutant pathogenic Atx1[82Q] human allele. 
(A) Bidirectional DNA construct with expression of only the membrane-targeted red 
fluorescent reporter GAPmScarlet under control of ca8 promoter-derived PC-
specific enhancer element. 
(B) Bidirectional DNA construct with coexpression of the human non-pathogenic 
protein Atx1[30Q] together with the membrane-targeted red fluorescent 
reporter GAPmScarlet under control of ca8 promoter-derived PC-specific 
enhancer element. 
(C) Bidirectional DNA construct with expression of the human SCA1-causing mutant 
protein Atx1[82Q] together with the membrane-targeted red fluorescent 
reporter GAPmScarlet under control of ca8 promoter-derived PC-specific 
enhancer element. 
The 2x4 copies of the enhancer element were added in opposite orientation and 
flanked on both sides with E1b basal promoter, multiple cloning site, 4 copies of 
mir181aT target fragment to eliminate ectopic expression in tectal neurons and 
retinal cells, and SV40 pA sequence. This mediated robust PC-specific expression of 
two different transgene cassettes. All bidirectional transgene cassettes were flanked 











3.1.2 Generation of stable transgenic zebrafish model for Purkinje 
cell-specific SCA1 
The three DNA constructs were separately microinjected into one-cell stage zebrafish 
embryos together with mRNA encoding the transposon Tol1 to promote genomic integration 
and germline transmission of the respective transgene cassettes early during development 
(Kikuta and Kawakami, 2009). At 4 dpf the injected larvae were screened and founders with 
broad GAPmScarlet expression throughout the PC population were raised to adulthood (P0 
generation). Germline transmission was examined by crossing individual P0 fish with wild-
type fish and screening of the filial F1 generation for PC-specific mScarlet fluorescence. Such 
carriers were raised to adulthood and crossed with wild-type fish to confirm stable 
transmission of the fluorescent reporter to the F2 offspring in a mendelian ratio (Fig. 3.2). 
Transgenic embryos of the F2 generation when analyzed at 4 dpf by laser scanning confocal 
microscopy were found to display continuous non-mosaic expression of the fluorescent 
reporter GAPmScarlet throughout the PCL (Fig. 3.3a-c). 
To confirm that the expression is specific for PCs, adult carriers from the three strains were 
crossed with carriers from the Tg(-7.5ca8:GFP)
bz12
 transgenic line which expresses GFP 
specifically in PCs (Namikawa et al., 2019). The transgenic embryos obtained from this 
mating showed double positive expression of red and green fluorescent proteins in PCs when 
they were analyzed at 4 dpf by laser scanning confocal microscopy (Fig. 3.3a-f). 
Colocalization of the red flourescence (GAPmScarlet) and the green fluorescence (GFP) in 
the cytoplasmic membrane and the cytoplasm of PCs, respectively, and the nonexistence of 
any unspecific red signal proved that transgene expression in the three established lines was 







Figure 3.2 Generation of stable transgenic zebrafish model for PC-specific SCA1 
Schematic outline of screening and breeding procedure performed to obtain stable 
transgenic zebrafish of the F2 generation, which propagate PC-specific mScarlet and 
Atx1 expression in a Mendelian manner. The generation of each of the three 
transgenic lines established in this study started with injecting the associated 
cloned DNA construct together with mRNA encoding the transposon Tol1 into wild-
type zebrafish zygotes at 0 dpf. The injected larvae which showed red fluorescence 
in PCs at 4 dpf were raised in the fish facility to get adult P0 generation carriers at 3 
months post fertilization (mpf). Such adults were screened by crossing with wild-
type fish and the offspring were checked for red fluorescence in PCs. The positive 
carriers were raised to get adult F1 generation fish. Afterwards, these adult fish 
were crossed with wild-type fish to raise and analyze F2 generation carriers starting 
after the beginning of PC differentiation in 4 dpf larval stage, then at early and late 






Figure 3.3 Expression pattern of GAPmScarlet in the established transgenic strains 
compared with PC-specific GFP in the transgenic strain Tg(-7.5ca8:GFP)bz12  
Analysis of membrane-targeted GAPmScarlet expression (a-c) compared with PC-
specific GFP cytoplasmic expression (d-f) and their colocalization in PCs (g-i) in 4 dpf 
embryos of the F2 generation of the established control (upper row), Atx1[30Q] 
(middle row) and Atx1[82Q] (lower row) transgenic strains. These results show that 
transgene expression in the three generated strains is confined to PCs. The images 
display a dorsal view of the larval zebrafish cerebellum, anterior is to the left. Scale 




3.1.3 Expression of human Ataxin-1 in the stable transgenic 
zebrafish strains 
To investigate whether GAPmScarlet fluorescence in PCs was accompanied by protein 
expression of the human Atx1 allele, HA-immunohistochemistry was performed. In the 
Atx1[30Q] transgenic 4 dpf larval zebrafish, the expression of non-pathogenic HA-tagged 
hAtx1[30Q] with normal number of polyQ repeats was observed in PCs throughout the entire 
PC population after immunostaining against HA-tag. GAPmScarlet red fluorescent reporter 
protein was observed as well in the cytoplasmic membranes of zebrafish PCs (Fig. 3.4A). In 
the Atx1[82Q] transgenic 4 dpf larval zebrafish, the expression of pathogenic mutant HA-
tagged hAtx1[82Q] with abnormal number of polyQ repeats was observed in PCs throughout 
the entire PC population after immunostaining against HA-tag. GAPmScarlet red fluorescent 
reporter protein was observed as well in the cytoplasmic membranes of zebrafish PCs (Fig. 
3.4B). Both HA-tagged human proteins, Atx1[30Q] and Atx1[82Q], showed aggregates in 
PCs (Fig. 3.4A, B, respectively, white arrows). 
This analysis revealed that human Atx1[30Q] and Atx1[82Q] were coexpressed with 
GAPmScarlet in PCs throughout the entire population indicating that GAPmScarlet serves as 
a reliable intravital marker for human Atx1-allele expression. Such expression of human 
SCA1-causing Atx1[82Q] protein in zebrafish Purkinje neurons in a stably inherited manner 
through fish generations is the first step towards modeling of the SCA1 inherited disorder in 
zebrafish. Expression of human non mutant Atx1[30Q] protein in zebrafish Purkinje neurons 
in a similar stably inherited manner through fish generations offers a baseline control for 
proper comparisons with SCA1 fish in the different experiments. It is also important to 
mention that no signs of neurodegeneration were detected in PCs of the Atx1[82Q] transgenic 













Anti-HA immunostaining of the HA-tagged proteins, hAtx1[30Q] (A) and hAtx1[82Q] 
(B), shows their expression in PCs (green fluorescence) in 4 dpf larvae of the F2 
generation of the established transgenic Atx1[30Q] and Atx1[82Q] strains, 
respectively. Such green signals are surrounded by the PC-specific membrane-
localized red fluorescent protein GAPmScarlet (white arrows). The images display a 



















3.2 Neurodegenerative effects of the overexpression of 
human mutant Ataxin-1 on zebrafish Purkinje cells 
In order to reveal the effect of transgene expression on developing and mature PCs, 
heterozygous F2 offspring of the control, Atx1[30Q] and Atx1[82Q] stable transgenic strains 
were raised. Expression of the red fluorescent membrane-targeted GAPmScarlet in PCs was 
investigated by confocal microscopy. Embryonic development appeared to occur 
indistinguishably between control fish, Atx1[30Q] fish expressing the human non-pathogenic 
allele with a polyQ stretch of 30 non-interrupted glutamine residues and Atx1[82Q] fish 
expressing the human pathogenic allele with a polyQ stretch of 82 non-interrupted glutamine 
residues. Larvae from all three alleles displayed a continuous bright red fluorescence 
throughout the PC population. Therefore, transgenic carriers were raised to early juvenile (40 
dpf) (Fig. 3.5), late juvenile (2 mpf) (Fig. 3.6) and young adult (3 mpf) (Fig. 3.7) stages. At 
these time points, the brains were dissected for microscopy analysis of PCs at further detail. 
PCs still expressed the red fluorescent reporter protein confirming the continued expression of 
the transgene throughout adulthood as demonstrated previously (Namikawa et al., 2019). 
At 40 dpf PCs in the control (Fig. 3.5a), Atx1[30Q] (Fig. 3.5b) and Atx1[82Q] (Fig. 3.5c) 
heterozygous transgene carriers formed a continuous layer covering the corpus cerebelli with 
both cerebellar hemispheres being separated by the dorsal midline (Fig. 3.5a white dashed 
line). No major signs of cerebellar atrophy like shrinkage in tissue or discontinuous patches of 
fluorescent PCs could be identified at this developmental age. Nevertheless, in contrast to 
controls and Atx1[30Q] zebrafish, confocal microscopy of the PC population in Atx1[82Q]-
expressing juveniles depicted speckles of brighter fluorescence suggestive of aggregation, 
cellular shrinkage and onset of neurodegeneration. This could be confirmed with a higher 
magnification imaging of selected PC areas (Fig. 3.5a-c, white squares) showing individual 
cells (Fig. 3.5d-f). PCs expressing Atx1[82Q] showed abnormal morphology (Fig. 3.5f, white 
arrows). However, PCs expressing Atx1[30Q] (Fig. 3.5e, white arrows) or GAPmScarlet only 
(Fig. 3.5d, white arrows) showed regular morphology with no signs of neurodegeneration. 
In late juvenile fish of 2 months of age the controls (Fig. 3.6a) and Atx1[30Q] (Fig. 3.6b) fish 
displayed a continuous PC population marked by red fluorescence in both hemispheres. This 
regularity and continuity of PC population in both hemispheres of the corpus cerebelli 




continuous layer of red fluorescent cells (Fig. 3.7a, b). In contrast to this, 2 months old 
juvenile Atx1[82Q] fish showed irregularities in their fluorescent PC population with signs of 
neurodegeneration based on the observance of areas of decreased or even absent red 
fluorescence (Fig. 3.6c). In order to show such irregularities on the cellular level, higher 
magnification imaging of selected cerebellar regions was performed (Fig. 3.6a-c, white 
squares). This revealed substantial difference among PCs in the SCA1 juveniles (Fig. 3.6f, 
white arrows), which displayed robust onset of neurodegeneration, and PCs in the control 
(Fig. 3.6d, white arrows) and Atx1[30Q] (Fig. 3.6e, white arrows) juveniles, which displayed 
normal appearance. 
Furthermore, young adults showed an escalation of such abnormalities where the PC 
population in Atx1[82Q] carriers was significantly disrupted with a severely disturbed outline, 
large discontinuities of cells, a small size and a granular appearance (Fig. 3.7c). Confocal 
microscopy of selected PC areas at higher magnification (Fig. 3.7c, white square) revealed 
condensed PC somata of unusually bright fluorescence likely caused by cell shrinkage and 
condensation of the fluorophore (Fig. 3.7f, white arrows) and fluorescent cellular debris 
indicative for an ongoing degeneration of PCs, while in control (Fig. 3.7a) and Atx1[30Q] 
carriers (Fig. 3.7b) a regular PC population was observed. Having a closer look at selected 
areas of PC region in these control transgenic strains (Fig. 3.7a, b, white squares), the 
individual PCs displayed a regular morphology with neither condensed cell somata of 
unusually bright fluorescence nor cellular debris (Fig. 3.7d, e). In addition, a fine web of 







Figure 3.5 Neurodegenerative effects of overexpression of the human mutant Atx1[82Q] 
on Purkinje cells of the early juvenile zebrafish 
Morphology of zebrafish cerebellum at 40 dpf juveniles of the F2 generation of the 
established transgenic strains (a-c), shown by the PC-specific membrane-targeted 
red fluorescent protein GAPmScarlet, reveals signs of neurodegeneration of PC 
population in the SCA1 transgenic zebrafish (right column) when compared to the 
control (left column) and Atx1[30Q] (middle column) transgenic strains. On the 
cellular level (d-f), there are signs of neurodegeneration of PCs in the Atx1[82Q] 
transgenic strain (f, white arrows) which are not observed in control (d, white 
arrows) and Atx1[30Q] (e, white arrows) strains. These data suggest that signs of PC 
neurodegeneration started to appear at the early juvenile stages expressing human 
pathogenic Atx1[82Q]. The images are representative for each experimental group 
(n = 7, 7 and 6 in the control, Atx1[30Q] and Atx1[82Q] groups, respectively) and 
display a dorsal view of early juvenile zebrafish cerebellum, anterior is to the left. 






Figure 3.6 Neurodegenerative effects of overexpression of the human mutant Atx1[82Q] 
on Purkinje cells of the late juvenile zebrafish 
Morphology of zebrafish cerebellum at 2 mpf (months post fertilization) juveniles of 
the F2 generation of the established transgenic strains (a-c), shown by the PC-
specific membrane-targeted red fluorescent protein GAPmScarlet, reveals signs of 
neurodegeneration of PC population in the SCA1 transgenic zebrafish (right column) 
when compared to the control (left column) and Atx1[30Q] (middle column) 
transgenic strains. On the cellular level (d-f), there are signs of neurodegeneration 
of PCs in the Atx1[82Q] transgenic strain (f, white arrows) which are not observed 
in control (d, white arrows) and Atx1[30Q] (e, white arrows) strains. These data 
suggest that neurodegeneration of PCs is clearly observed at the late juvenile 
stages expressing human pathogenic Atx1[82Q]. The images are representative for 
each experimental group (n = 6, 6 and 7 in the control, Atx1[30Q] and Atx1[82Q] 
groups, respectively) and display a dorsal view of late juvenile zebrafish cerebellum, 






Figure 3.7 Severe neurodegeneration of Purkinje cell population in the adult SCA1 
transgenic zebrafish  
Morphology of zebrafish cerebellum at 3 mpf (months post fertilization) juveniles of 
the F2 generation of the established transgenic strains (a-c), shown by the PC-
specific membrane-targeted red fluorescent protein GAPmScarlet, reveals signs of 
neurodegeneration of PC population in the SCA1 transgenic zebrafish (right column) 
when compared to the control (left column) and Atx1[30Q] (middle column) 
transgenic strains. On the cellular level (d-f), the PC population in the Atx1[82Q] 
transgenic strain is significantly affected with a severely disturbed outline, large 
discontinuities of cells, a small size and a granular appearance (f, white arrows). 
Such irregularities were not observed in control (d, white arrows) and Atx1[30Q] (e, 
white arrows) strains. These data suggest that neurodegeneration of PCs is clearly 
observed at the adult stages expressing human pathogenic Atx1[82Q]. The images 
are representative for each experimental group (n = 6, 6 and 7 in the control, 
Atx1[30Q] and Atx1[82Q] groups, respectively) and display a dorsal view of adult 





The robust disruption of the PCL in the adult Atx1[82Q] carriers was further revealed by the 
cerebellar sagittal sections. Although the membrane-targeted expression of mScarlet showed a 
continuous layer of PCs in the control and Atx1[30Q] strains (Fig. 3.8a, b), in SCA1 fish red 
fluorescent PCs were largely absent, almost entirely in anterior regions of the corpus cerebelli 
while the posterior region still contained a number of PCs (Fig. 3.8c). To further corroborate 
that the SCA1 zebrafish model suffer from PC neurodegeneration, sagittal sections from the 
cerebellum of control, Atx1[30Q] and Atx1[82Q] adult fish were stained with anti-ZebrinII 
immunostainig, a specific antibody staining for PCs (Brochu et al. 1990). Such sections 
displayed disrupted cellular organization in the PCL of Atx1[82Q] fish with apparent holes 
and debris compared to sections from the control alleles (Fig. 3.8d-f). 
Moreover, sagittal sections of the PCL in Atx1[30Q] and Atx1[82Q] zebrafish analyzed by 
anti-HA immunohistochemistry confirmed that the transgenes were still expressed in PCs 
during adulthood, yet displaying only sparse labelling in PCs of Atx1[82Q] carriers consistent 
with apparent holes in the PCL, cellular debris and pronounced PC degeneration (Fig. 3.8g, 
h). These results further support the age-dependent progredient loss of PCs in the Atx1[82Q] 
SCA1 fish as it is observed in SCA1 patients. These findings also confirm an observation 
from juvenile stages that apparently anterior regions of the corpus cerebelli seem more 
vulnerable for PC degeneration than posterior regions in this zebrafish SCA1 model. 
In addition, histological staining of adult brain sagittal sections with hematoxylin and eosin 
was performed. It was shown that the pathogenic cellular organization of Atx1[82Q] PCs does 
not seem to affect the gross morphology of the corpus cerebelli (Fig. 3.9a-c). At higher 
magnifications (Fig. 3.9d-f), large somata (Fig. 3.9d, e, white arrows) characteristic for PCs, 
between the granule cell layer (GCL) and the molecular layer (ML), were only visible in the 
cerebelli of control and Atx1[30Q] transgenic strains, but were hardly found in the cerebelli of 
Atx1[82Q] transgenic strain. These results revealed the undisturbed cytology of the 
cerebellum in the SCA1 zebrafish model with an obviously-distinguishable GCL and ML 









Figure 3.8 Immunohistochemical comparison of adult corpus cerebelli of control and Atx1-
expressing zebrafish 
(a-c) Sagittal sections from the cerebellum of control, Atx1[30Q] and Atx1[82Q] 
adult zebrafish, respectively. 
(d-f) PC-specific anti-ZebrinII antibody staining of sagittal sections from the 
cerebellum of control, Atx1[30Q] and Atx1[82Q] adult zebrafish, respectively. 
(g, h) Anti-HA immunostaining of sagittal sections from the cerebellum of Atx1[30Q] 
and Atx1[82Q] adult zebrafish, respectively. 











Figure 3.9 Histological comparison of adult corpus cerebelli of control and Atx1-expressing 
zebrafish 
(a-c) Hematoxylin-Eosin staining of sagittal sections from the cerebellum of control, 
Atx1[30Q] and Atx1[82Q] adult zebrafish, respectively. 
(d-f) Higher magnification of a-c, respectively. 









3.3 Age-related progredient loss of Purkinje cell 
population in zebrafish genetic ‎A S f‎ l‎dom1 
Long term analysis was performed for fish groups from the F2 generation of the established 
transgenic control, Atx1[30Q] and Atx1[82Q] strains at 40 dpf (early juvenile stage), 2 mpf 
(late juvenile stage) and 3 mpf (adult stage). At these time points, the body length form the 
anterior tip of the jaw until the caudal indentation of the tail fin (fork length) of each fish was 
measured (Fig. 3.10A). This was followed by isolation of the brain for microscopy analysis of 
PCs and quantification of the brain area covered by PCs across the corpus cerebelli at each 
age under investigation (Fig. 3.10B). The body length at each time point did not differ 
significantly among individuals from all three allelic families and the growth in body length 
continued regularly until adulthood in control and Atx1[30Q] zebrafish as well as Atx1[82Q] 
zebrafish (Fig. 3.11). 
                         
 
Figure 3.10 Analysis of fish body length and dorsal surface of the cerebellum in dissected 
brains 
(A) Schematic drawing of adult zebrafish to demonstrate measurement of body 
length form the anterior tip of the jaw until the caudal indentation of the tail fin 
(fork length) before dissection (lateral view). 
(B) The cerebellum in dissected brains from these specimens is easy to identify by 
the red fluorescent PC population forming a continuous layer of cells across the 
corpus cerebelli providing a means for measuring the dorsal surface of the 
cerebellum (dorsal view). 
Abbr.: Cb: cerebellum, TeO: optic tectum, Tel: telencephalon. 
 
When the fluorescent cerebellar area covered by PCs (Fig. 3.10B, red area) was quantified 





using two-way ANOVA with post hoc Tukey's test, a reduced size of this area was observed 
only in the Atx1[82Q] transgenic strain. This reduction in size of the PC area occurred in an 
age-dependent progredient manner as the size of PC area stalled in the SCA1 fish from 40 dpf 
to 2 mpf and there was a significant reduction at 3 mpf. Nevertheless, the area covered by PC 
population in the control and Atx1[30Q] strains increased significantly from 40 dpf to 2 mpf 
and from 2 mpf to 3 mpf. Moreover, the Atx1[30Q] strain never showed a significant 
difference from the control strain at any time point, which suggests that the transgenic fish 
expressing non-pathogenic human protein Atx1[30Q] display a regular development of PC 
population (Fig. 3.12). At 40 dpf, the statistical analysis revealed no significant differences in 
size of the PC area among fish from all three groups, although signs of neuronal degeneration 
have been already seen in the SCA1 model. This further confirmed the absence of a major 
cerebellar atrophy in SCA1 zebrafish at 40 dpf (Fig. 3.12). 
The impaired age-dependent expansion of the PC population in the SCA1 fish was obvious 
because the size of the PC area barely increased in 2 mpf juveniles in comparison to 40 dpf 
juveniles (Fig. 3.12) despite a regular age-related increase in body size (Fig. 3.11). In young 
adults, this situation progressed even further. Although the adult SCA1 fish have grown to 
their normal body size compared to the control and Atx1[30Q] counterparts (Fig. 3.11), the 
area covered by the PC population was quantified to be smaller than in both 40 dpf and 2 mpf 
SCA1 juveniles and about 5-fold smaller than in the adult control and Atx1[30Q] 
counterparts. However, zebrafish of the control and Atx1[30Q] strains displayed a comparable 
age-related expansion of the PC population in both hemispheres of the corpus cerebelli (Fig. 
3.12) in relation to the growth of their body (Fig. 3.11). This age-dependent increase in body 
length accompanied by an expansion of the PC area continued to young adulthood in 3 
months old fish. These findings suggest a progredient neurodegeneration of PCs in the SCA1 
zebrafish model expressing the human Atx1[82Q] allele in PCs, which like in human patients 






Figure 3.11 Body length analysis in a stable transgenic zebrafish model for SCA1 
Age-related analysis of the body length of fish groups from the F2 generation of the 
established transgenic control, Atx1[30Q] and Atx1[82Q] strains at early juvenile 
stage (40 dpf), late juvenile stage (2 mpf) and young adult stage (3 mpf). The body 
length among individuals from all three allelic families did not differ significantly at 
each time point. In addition, the growth in body length of the SCA1 zebrafish 
continued regularly until adulthood as same as the control and Atx1[30Q] zebrafish. 
These findings suggest that abnormal PC development in zebrafish expressing the 
human pathogenic Atx1[82Q] protein does not interfere with organismic growth. 
Data are presented as mean ± SEM. N = 7, 6, 6 in 40 dpf, 2 mpf and 3 mpf control 
groups; N = 7, 6, 6 in 40 dpf, 2 mpf and 3 mpf Atx1[30Q] groups; and N = 6, 7, 7 in 40 






Figure 3.12 Long term analysis of the area covered by Purkinje cell population in a stable 
transgenic zebrafish model for SCA1 
Long term analysis of PC region reveals a robust age-dependent progressive 
reduction in the cerebellar area covered by Purkinje neurons in the SCA1 zebrafish 
when compared to the control and Atx1[30Q] transgenic strains. Changes in the size 
of the PC population start in late juvenile stages (2 mpf), although signs of 
neurodegeneration can be observed already in early juvenile stages (40 dpf). These 
findings suggest a severe neurodegeneration of PCs in the zebrafish expressing the 
human Atx1[82Q] allele specifically in PCs, which like in human patients occurs in 
progressive, age-related manner. Data are presented as mean ± SEM; *p < 0.05, 
***p < 0.001 and ****p < 0.0001. N = 7, 6, 6 in 40 dpf, 2 mpf and 3 mpf control 
groups; N = 7, 6, 6 in 40 dpf, 2 mpf and 3 mpf Atx1[30Q] groups; and N = 6, 7, 7 in 40 








3.4 Physiological properties of zebrafish Purkinje cells 
expressing human Ataxin-1 
The morphological disruption of PCs in the SCA1 zebrafish model has been observed to 
initiate at 40 dpf (Fig. 3.5d-f). There were no signs of neurodegeneration observed at younger 
ages. This led to an important question whether the physiology of PCs has already been altered 
prior to such morphological disruption. To answer this question, in vivo calcium imaging was 
performed to evaluate the activity of PCs in larval stages using the advantage of transparency 
of the larvae. In order to generate zebrafish expressing a fluorescent indicator for Ca
2+
 





 carriers. The 
obtained larvae were expressing exclusively in PCs two fluorescent proteins, mScarlet (red) in 
the cell membrane and GFP (green) in the cytoplasm. The green fluorescence is indicating the 
Ca
2+
 indicator GCaMP6s. The recording of fluorescent emission of this Ca
2+
 indicator in the 
PCL was performed for 333 seconds in 6 dpf and 12 dpf larval zebrafish. It was performed for 
5 planes (each 10 µm apart) of the PCL, and the GCaMP6s fluorescent emission was analyzed 
in the third PC plane of all fish (Fig. 3.14E). 
It was observed that Ca
2+
 transients in PCs at 6 dpf displayed a disrupted activity in the SCA1 
zebrafish. The Atx1[82Q]-expressing larvae displayed abnormal pattern of PC neuronal 
activity when compared to the control and Atx1[30Q]-expressing larvae (Fig. 3.13A). At 12 
dpf, not only Atx1[82Q]-, but also Atx1[30Q]-expressing larvae showed altered activity of 
Ca
2+
 transients in PCs when compared to the control larvae (Fig. 3.13B). Having a closer look 
at a representative one minute of Ca
2+
-transient activity in PCs from a single fish per group, 
the observation of the disrupted activity in the SCA1 fish was confirmed. This representative 
minute was taken from the middle of the image recording period starting after 160 seconds of 
recording. The PC activity, indicated by the fluorescent emission of the Ca
2+
 indicator 
GCaMP6s, in the Atx1[82Q] strain at 6 dpf seemed to be weaker than both the control and the 
Atx1[30Q] strains that showed almost similar activity pattern (Fig. 3.14A). However, the 
Atx1[30Q] and the Atx1[82Q] transgenic strains displayed affected physiology at 12 dpf  (Fig. 
3.14B). 
Two-way ANOVA with post hoc Tukey's test was performed to compare zebrafish groups 




the Atx1[82Q] strain at 6 dpf was reduced with significant differences from the control and the 
Atx1[30Q] strains (Fig. 3.14C). Interestingly, later at 12 dpf, there was no significant 
difference between the Atx1[30Q] and Atx1[82Q] transgenic strains. Nevertheless, both of 
them displayed altered activity with significant differences from the control strain (Fig. 
3.14D). The results of calcium imaging suggest that the affected morphology followed by 
neurodegeneration of zebrafish PCs expressing the human SCA1-causing Atx1[82Q] allele 
was pre-accompanied with an early disruption in the PC physiology. In addition, 
overexpression of the human non-pathogenic Atx1[30Q] allele also seems to affect the 
physiology of zebrafish PCs, although it does not lead to neurodegeneration. Thus, the human 




















Figure 3.13 Altered neuronal activity of the larval SCA1-affected PCs 
(A) At 6 dpf, the fluorescent emission of the calcium indicator GCaMP6s in the 
PCL of a fish group from each transgenic strain over 265 seconds indicates 
an abnormally-decreased neuronal activity in the Atx1[82Q] strain. N = 7, 8, 






(B) At 12 dpf, the fluorescent emission of the calcium indicator GCaMP6s in the 
PCL of a fish group from each transgenic strain over 265 seconds indicates 
an abnormally-decreased neuronal activity not only in the Atx1[82Q] strain, 
but also in the Atx1[30Q] strain. N = 6, 6, 7 in control, Atx1[30Q] and 
Atx1[82Q] groups, respectively. 











































Figure 3.14 Purkinje neurons display disrupted physiology in the Atx1[82Q] and Atx1[30Q] 
transgenic strains starting either at 6 dpf or at 12 dpf, respectively 
(A) Representative one-minute data of calcium-transient activity in the PCL of 
individual larva from each transgenic strain at 6 dpf reveal a decreased 
neuronal activity in the Atx1[82Q] strain. 
(B) Representative one-minute data of calcium-transient activity in the PCL of 
individual larva from each transgenic strain at 12 dpf reveal a decreased 
neuronal activity not only in the Atx1[82Q] strain, but also in the Atx1[30Q] 
strain. 
(C) Quantitative data analysis of calcium-transient activity in the PCL at 6 dpf 
confirms the disrupted neuronal physiology in the Atx1[82Q] strain. N = 7, 8, 







(D) Quantitative data analysis of calcium-transient activity in the PCL at 12 dpf 
confirms the disrupted neuronal physiology not only in the Atx1[82Q] strain, 
but also in the Atx1[30Q] strain. N = 6, 6, 7 in control, Atx1[30Q] and 
Atx1[82Q] groups, respectively. 
(E) Representative frame shows the stack calcium imaging (5 planes each 10 µm 
apart) of the PCL by digital light-sheet microscopy. The fluorescent emission 
of the Ca2+ indicator GCaMP6s was analyzed in the third PC plane of all fish. 
Each color in A-D represents a transgenic strain. Data in C and D are presented 

















3.5 SCA1 zebrafish display behavioral abnormalities  
SCA1 zebrafish tended to swim at the bottom of their tanks in the fish facility in case of 
exposure to any disturbance such as moving the tank to take out some fish for crossing or for 
an experiment. Therefore, a specific behavioral test to assess such phenotype was needed. The 
novel tank diving test is a behavioral test used to characterize the exploratory behavior in 
zebrafish. It exploits the natural tendency of zebrafish to initially dive to the bottom of a novel 
experimental tank, with a gradual increase in the vertical exploratory activity over time. The 
novel tank diving test is a comprehensively-studied model for evaluating zebrafish 
exploratory behavior in a novel environment (Maximino et al. 2010). 
Therefore, age-dependent behavioral analysis in the novel tank diving test at 40 dpf, 2 mpf 
and 3 mpf was performed for fish groups from the control, Atx1[30Q] and Atx1[82Q] strains. 
During 6-minute video recording for each individual fish in the novel tank diving test, the 
aspects that express the exploratory behavior such as the percentage of time spent in the upper 
half of the tank (Fig. 3.15), the latency until the first visit to the upper half (Fig. 3.16) and the 
minimum swimming velocity (Fig. 3.17) were measured. Additionally, the whole distance 
traveled in the novel tank (Fig. 3.18A), the number of transitions to the upper half (Fig. 
3.18B), the average swimming velocity (Fig. 3.18C) and the maximum swimming velocity 
(Fig. 3.18D) were measured to evaluate the locomotor activity. Two-way ANOVA with post 
hoc Tukey's test was used for data analysis. 
On the one hand, the elements indicting the exploratory behavior showed interesting results. 
Zebrafish expressing the human Atx1[82Q] allele specifically in PCs tended to spend less 
percentage of time in the upper half of the novel tank during the 6-minute test, when 
compared to the control and Atx1[30Q] transgenic strains (Fig. 3.15). Changes in time spent 
in the upper half started at late juvenile stage (2 mpf) and increased at adult stage (3 mpf). 
However, at early juvenile stage (40 dpf), there were no significant differences between the 
three fish strains. In addition, despite the significant increase in the time spent in upper half 
from 40 dpf to later stages in the control groups, the SCA1 fish showed non-significant 
increase from 40 dpf to 2 mpf and decrease at 3 mpf (Fig. 3.15). These data suggest that 
SCA1-affected zebrafish show age-dependent progressive reduction in the exploratory 
behavior indicated by the progressive escalation of the difference from the control groups in 







Figure 3.15 Age-dependent analysis of time spent in the upper half during the novel tank 
diving test for a stable transgenic zebrafish model for SCA1 
(A) Representative profile of tracked movements of a 3-mpf individual fish in the 
novel tank for 6 minutes displays the exploration of the upper half by the 
fish from control strains and the preference of the Atx1[82Q] fish to remain 
in the bottom for almost the entire recording period. 
(B) Long term analysis of zebrafish behavior in the novel tank diving test reveals 
that fish expressing the human Atx1[82Q] allele specifically in PCs showed 
non-significant increase from 40 dpf to 2 mpf and decrease at 3 mpf in the 
percentage of time spent in the upper half of the tank during the 6-minute 
test, although the control groups showed significant increase in the time 
spent in upper half from 40 dpf to older stages. Data are presented as mean 
± SEM; ***p < 0.001 and ****p < 0.0001. N = 14, 10, 10 in 40 dpf, 2 mpf and 
3 mpf control groups; N = 13, 12, 11 in 40 dpf, 2 mpf and 3 mpf Atx1[30Q] 







SCA1 zebrafish did not display significant decrease from 40 dpf to 2 mpf regarding the time 
spent in the lower half of the novel tank before the first exploration of the upper half (latency 
to the first upper visit) (Fig. 3.16). However, the control and Atx1[30Q] transgenic strains 
displayed significant decrease in such latency from 40 dpf to 2 mpf. Nevertheless, not only 
the Atx1[82Q] but also the control and Atx1[30Q] transgenic strains showed non-significant 
decrease in the latency to the first upper visit from 2 mpf to 3 mpf. These data also suggest 
that SCA1-affected zebrafish show a reduced exploratory behavior as they did not show 
significantly faster movement to the upper half of the tank from 40 dpf to 2 mpf as shown in 
the control groups (Fig. 3.16). 
 
 
Figure 3.16 Age-dependent analysis of latency until first visit to the upper half at the novel 
tank diving test for a stable transgenic zebrafish model for SCA1  
Long term analysis of zebrafish behavior in the novel tank diving test reveals that 
fish expressing the human Atx1[82Q] allele specifically in PCs showed non-
significant decrease in the latency until the first exploration of the upper half from 
40 dpf to 2 mpf. The control and Atx1[30Q] transgenic strains showed significant 
decrease. Data are presented as mean ± SEM; *p < 0.05 and **p < 0.01. N = 14, 10, 
10 in 40 dpf, 2 mpf and 3 mpf control groups; N = 13, 12, 11 in 40 dpf, 2 mpf and 3 





Furthermore, fish expressing the human Atx1[82Q] allele specifically in PCs did not display 
significant increase in the minimum velocity from early juvenile (40 dpf) to adult stage (3 
mpf) (Fig. 3.17). However, the control and Atx1[30Q] transgenic strains displayed significant 
increase in the minimum velocity from early juvenile to adult stage. Although the difference 
between SCA1 fish and control fish at the juvenile stages (40 dpf and 2 mpf) was not 
significant, there was a significant difference between adult SCA1 fish and adult control fish. 
These data confirm that SCA1-affected zebrafish show a reduced exploratory behavior 
indicated by the tendency to freeze in such a novel environment (Fig. 3.17). 
 
 
Figure 3.17 Age-dependent analysis of minimum velocity during the novel tank diving test 
for a stable transgenic zebrafish model for SCA1  
Long term analysis of zebrafish behavior in the novel tank diving test reveals that 
the Atx1[82Q] transgenic fish displayed non-significant increase in the minimum 
velocity from 40 dpf to 3 mpf. The control and Atx1[30Q] transgenic strains 
displayed significant increase in the minimum velocity from 40 dpf to 3 mpf. Data 
are presented as mean ± SEM; *p < 0.05 and ***p < 0.001. N = 14, 10, 10 in 40 dpf, 
2 mpf and 3 mpf control groups; N = 13, 12, 11 in 40 dpf, 2 mpf and 3 mpf 






On the other hand, when parameters for locomotor activity were analyzed, SCA1 fish did not 
show significant differences from the control strains at all stages in number of transitions or in 
average and maximum velocity (Fig. 3.18B-D). However, regarding the distance traveled, 
although the control strains showed significant increase from early (40 dpf) to late (2 mpf) 
juvenile stages, the SCA1 fish did not (Fig. 3.18A). These data suggest that SCA1-affected 
zebrafish are able to move almost as same as the control strains without obvious locomotor 






Figure 3.18 Age-dependent analysis of distance traveled, velocity and number of 
transitions to the upper half in the novel tank diving test for a stable transgenic zebrafish 
model for SCA1 
Long Long term analysis of zebrafish behavior in the novel tank diving test reveals 
that fish expressing the human Atx1[82Q] allele specifically in PCs did not display 
obvious locomotor deficits. However, they showed some difference from the 
control strains as they did not show significant increase in the whole distance 
traveled in the novel tank from 40 dpf to 2 mpf. 






(B) Analysis of the number of transitions to the upper half. 
(C) Analysis of the average velocity. 
(D) Analysis of the maximum velocity. 
Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. N = 14, 10, 10 in 40 dpf, 2 mpf and 3 mpf control groups; N = 
13, 12, 11 in 40 dpf, 2 mpf and 3 mpf Atx1[30Q] groups; and N = 15, 13, 10 in 40 





4.1 Genetic modeling of SCA1 in zebrafish 
The detailed molecular mechanisms behind polyQ-expanded Atx1 pathogenesis are still 
unknown (Rousseaux et al. 2018; Lee et al. 2021). In addition, there are at present no disease-
modifying cures that exist for SCA1 patients being managed by palliative care only (Bondar et 
al. 2018; Nitschke et al. 2021). The Atx1 gene family in zebrafish was characterized and two 
homologs were identified, Atx1a and Atx1b, which are conserved in the human Atx1 gene and 
expressed in the zebrafish cerebellum; the vulnerable site of SCA1 pathogenesis in humans 
(Carlson et al. 2009b). Therefore, Carlson and his colleagues suggested that SCA1 can be 
genetically modeled in zebrafish resulting in a useful model for studying the pathology of 
SCA1 as well as screening of the toxicity and bioactivity of many candidate drugs before 
testing on large animal models. In this study, a genetic disease model for SCA1 in zebrafish 
was generated. Such a novel model with unique features, together with the other established 
models, will make it easier to better understand the pathological mechanisms, to follow the 
disease progression in vivo, to identify druggable targets, and to faster screen various 
candidate therapeutic and neuroprotective compounds. 
In order to model the SCA1 human disease in zebrafish, a stable transgenic strain expressing 
the human mutant Atx1[82Q] protein was generated and a systematic analysis was performed 
in the larval stage (6 dpf and 12 dpf), the juvenile stage (40 dpf and 2 mpf) and the adult stage 
(3 mpf). Furthermore, as a control, another two stable transgenic strains were established 
expressing either the red fluorescent protein GAPmScarlet (Bindels et al. 2017) only or the 
human non-pathogenic Atx1[30Q] protein together with GAPmScarlet. The results revealed 
pathological phenotypes in the Atx1[82Q] strain that started from the early larval stages and 
got progressively worse. At the larval stages, physiological abnormalities in the activity of PCs 
were observed. Afterwards, SCA1 zebrafish started to display neurodegeneration of PCs at the 
early juvenile stage without showing behavioral deficits. Late juvenile as well as adult stages 






4.2 Neurodegenerative effects of the polyglutamine toxicity 
Some neurodegenerative diseases are characterized by abnormal folding and aggregation of 
the polyQ-containing proteins due to aberrant expansion of CAG-repeat sequence in the 
coding region of the corresponding genes, that translates into a long polyQ tract in the proteins 
(Fan et al. 2014). The length of the expanded CAG repeats may increase while passing from 
one generation to the next. These so-called polyQ diseases exhibit superior degeneration of 
specific cell types, in spite of the wide expression of the mutant genes in various cell types. 
The polyQ neurodegenerative disorders display disease onset in midlife which gets 
progressively worse (Lieberman et al. 2019). As yet, nine polyQ disorders have been 
identified: six SCA types 1, 2, 3, 6, 7, 17; Huntington’s disease (HD); spinal and bulbar 
muscular atrophy (SBMA); and dentatorubral pallidoluysian atrophy (DRPLA) (Fan et al. 
2014; Lieberman et al. 2019). It has been shown over recent years that the toxicity of polyQ 
SCAs is induced mainly by genetic and epigenetic deregulations (Niewiadomska-Cimicka et 
al. 2020). 
In order to understand the pathological mechanisms behind polyQ toxicity, various animal 
models for polyQ disorders were established. Animal models for SCA1 started to be generated 
after the identification of the SCA1 causative gene (Zoghbi et al. 1991; Ranum et al. 1991) and 
the gene’s mutation involved in the protein’s pathogenesis, which is the abnormal expansion 
of the trinucleotide CAG repeats resulting in an extended polyQ tract (Orr et al. 1993). As a 
first SCA1 model, a stable transgenic neurodegeneration model in mice could be successfully 
generated by expressing the human mutant gene Atx1[82Q] with an expanded CAG tract 
specifically in PCs (Burright et al. 1995). As in the current study, Burright and his colleagues 
generated another transgenic animal expressing the human non-pathogenic gene Atx1[30Q] 
with a normal CAG tract as control. The findings of the current study are consistent with theirs 
as the hAtx1[82Q]-expressing mice and zebrafish displayed PC neurodegeneration and 
consequently behavioral deficits, while the hAtx1[30Q]-expressing mice and zebrafish did not. 
The study by Burright and coworkers (1995) stated that the pathological mechanism behind 
neurodegeneration caused by polyQ expansions is unclear. However, it reported that the 
neurodegeneration phenotype observed in SCA1 transgenic mice carrying human mutant Atx1 
cDNA obviously reveals that PCs of mice are susceptible to SCA1 pathological mechanisms 




neurodegeneration phenotype observed in SCA1 transgenic zebrafish carrying human mutant 
Atx1 cDNA indicate that PCs of zebrafish are susceptible to SCA1 pathological mechanisms 
and that the cellular proteins involved in SCA1 pathology are also conserved in zebrafish.  
Moreover, it was shown by immunostaining of human Atx1 protein in transgenic mice using 
anti-Atx1 antisera that human Atx1 was only detectable in Atx1[30Q]-expressing mice at 
different ages between 6 and 24 weeks old. However, human Atx1 was not detectable at all in 
Atx1[82Q]-expressing mice at different ages between 4 and 19 weeks old (Burright et al. 
1995). Interestingly, the immunostaining of the HA-tagged human Atx1 protein in the current 
zebrafish model showed that human Atx1 was detectable in Atx1[30Q]-expressing zebrafish at 
4 dpf (Fig. 3.4A) and at the adult stage (Fig. 3.8g). However, in Atx1[82Q]-expressing 
zebrafish, human Atx1 was only detectable in young PCs at 4 dpf (Fig. 3.4B) and almost 
entirely disappeared at the adult stage (Fig. 3.8h). It was concluded by Burright and his 
colleagues that mutant Atx1[82Q] expressed in PCs is either degraded or modified, and this 
might also be the situation in zebrafsh PCs. 
In terms of cellular proteins involved in SCA1 pathology, it was found that the nuclear 
accumulation of mutant polyQ-expanded Atx1 is insufficient for its pathogenesis. However, its 
pathogenesis is induced exclusively by the interaction with the transcriptional repressor CIC 
forming the polyQ-expanded Atx1-CIC large protein complex (Rousseaux et al. 2018). This 
complex exerted its toxicity in SCA1 patient-derived neurons and PCs of SCA1 transgenic 
mice by a gain-of-function pathological mechanism. This was concluded through an 
interesting experiment where the interaction between polyQ-expanded Atx1 and CIC was 
disrupted in Atx1[82Q]V591A;S602D transgenic mice carrying the human pathogenic allele 
Atx1[82Q] with mutations of two critical residues in the AXH domain, valine 591 (V591A) 
and serine 602 (S602D). Such disruption resulted in the absence of cerebellar pathology, in 
spite of the presence of aggregates of mutant polyQ-expanded Atx1 in PCs (Rousseaux et al. 
2018). 
Atx1 forms also another large protein complex by binding to the RNA splicing factor RBM17 
(Lim et al. 2008). Mutant polyQ-expanded Atx1 has higher tendency to associate with RBM17 
than normal Atx1. Therefore, there was an increase in the polyQ-expanded Atx1-RBM17 
protein complexes in SCA1 transgenic mice that could result in irregular splicing of mRNA of 
important genes leading to neuronal dysfunction and death (Carlson et al. 2009a). 




2005; Chen et al. 2014; Mehjabin et al. 2019) might play a big role in the vulnerability of 
zebrafish PCs to SCA1 pathology through their interaction with the human mutant Atx1[82Q] 
which makes zebrafish a realistic model for SCA1. 
Furthermore, a Drosophila model for SCA1 was established where combinatorial genetics 
(GAL4/UAS system) was used to also express either the human wild-type Atx1[30Q] or the 
human pathogenic Atx1[820Q] genes in transgenic fruit flies in a controlled manner 
(Fernandez-Funez et al. 2000). However, the expression was directed to the retina of the eye. 
It was reported that the relatively high expression of the Atx1[30Q] allele can unexpectedly 
lead to pathological phenotypes as same as those produced by Atx1[820Q] allele (Fernandez-
Funez et al. 2000). These findings are not fully consistent with the current model where 
overexpression of the human Atx1[30Q] allele in zebrafish did not induce neurodegeneration 
like overexpression of the human Atx1[82Q] allele (Fig. 3.5, 3.6 and 3.7). 
In zebrafish, the first model for polyQ toxicity reported that zebrafish embryos can 
recapitulate the features of the human polyQ diseases, characterized by protein aggregation as 
well as polyQ length-dependent toxicity, through expressing polyQ tracts of different lengths 
(19Q, 35Q, 56Q and 80Q) fused to GFP in zebrafish embryos (Miller et al. 2005).  The 
Atx1[30Q] and Atx1[82Q] transgenic zebrafish strains in the current study replicated this 
polyQ length-dependent toxicity. On the one hand, the Atx1[82Q] strain started to show 
pathological phenotype in PCs at 6 dpf, earlier than the Atx1[30Q] strain which started to 
show similar pathological phenotype at 12 dpf (Fig. 3.13 and 3.14). On the other hand, the 
human mutant Atx1[82Q] induced neurodegeneration of PCs, while human wild-type 
Atx1[30Q] did not induce such neurodegeneration (Fig. 3.5, 3.6 and 3.7). As Miller and his 
colleagues expressed polyQ tracts non-specifically in zebrafish embryos, they recommended 
that developing specific expression systems in the nervous system of zebrafish is required for 
more precise polyQ disease modeling in such simple vertebrate (Miller et al. 2005). The 
current SCA1 model with PC-specific expression system could accomplish this goal. 
Additionally, transient transgenic zebrafish model for the human polyQ disease, Huntington 
disease, was generated (Schiffer et al. 2007). It was generated by injection of mRNA 
expressing an N-terminal fragment of the protein involved in Huntington disease containing 
different polyQ repeat numbers Htt[4Q], Htt[25Q] and Htt[102Q] into the first or second cell 
stage of zebrafish embryos. The Htt[4Q] and Htt[25Q] proteins did not show accumulated 




hours in most embryos reminiscent of the aggregates of both human proteins Atx1[30Q] and 
Atx1[82Q] observed in 4 dpf larvae (Fig. 3.4). Such polyQ disease model in zebrafish was 
generated in a transient manner by injecting the related mRNA in zebrafish embryos (Schiffer 
et al. 2007). Therefore, the current SCA1 model is a competitive model, offering a novel 
zebrafish model of a polyQ disease with a cell-specific expression of the involved pathogenic 
human protein in a stable transgenic manner, available for future studies. 
The neurodegeneration phenotype shown in the current study was getting stronger in an age-
related progredient manner (Fig. 3.12). This progressive phenotype highly mimics the 
progression of the human SCA1 disease which is known to be a progredient disease (Buijsen 
et al. 2019). Such progressive neurodegeneration phenotype in PCs was also shown in a 
zebrafish model for SCA13 (Namikawa et al. 2019b). Contrary to the findings in SCA1 
zebrafish, overexpression of the SCA13 disease causing gene kcnc3a
R355H
 within zebrafish 
PCs, under control of the same PC-specific enhancer element, resulted in robust 
neurodegeneration of zebrafish PCs in the SCA13 zebrafish model as early as 4 dpf. In order 
to establish the SCA13 model, Namikawa and his colleagues isolated a compact regulatory 
element of 258 bp, cpce. The cpce enhancer drives expression specifically in PCs. 2x2 Copies 
of this regulatory element were used to overexpress the SCA13 mutant gene in zebrafish PCs 
(Namikawa et al. 2019b), while 2x4 copies were used to overexpress the SCA1 mutant gene in 
PCs of the current SCA1 model. The neurodegeneration in the SCA13 model was clearly 
earlier than in the current SCA1 model in spite of the fewer copy number of the enhancer (2x2 
copies instead of 2x4). However, the progressive neurodegenertaion of PCs indicated by 
Namikawa and his colleagues in the SCA13 larvae at 4, 7, 11 and 14 dpf was in line with the 
progressive neurodegenertaion observed in the SCA1 fish in older stages at 40 dpf, 2 mpf and 
3 mpf. The difference in the starting age of the neurodegeneration phenotype might be due to 








4.3 Purkinje cell physiological deficits in the SCA1 
zebrafish model  
It was important to investigate whether the physiological properties of larval PCs in the SCA1 
zebrafish were affected by the expression of human Atx1[82Q]. Therefore, calcium imaging 
was performed to assess the activity of PCs and to resolve whether the larval PCs expressing 
either the human non-pathogenic allele Atx1[30Q] or the human disease-causing allele 
Atx1[82Q] were physiologically affected although they did not seem to be morphologically 
affected. Although Atx1[30Q] did not induce neurodegeneration as Atx1[82Q] did in juvenile 
and adult stages, both of the human proteins could induce physiological deficits in larval 
zebrafish PCs. This might be due to the presence of aggregates of both polyQ human proteins 
Atx1[30Q] and Atx1[82Q] in larval zebrafish PCs as early as 4 dpf (Fig. 3.4A, B, 
respectively). However, the difference between both transgenic strains was that the Atx1[82Q] 
strain started to display such deficits at younger ages than the Atx1[30Q] strain. At 6 dpf, the 
Atx1[82Q] strain showed weaker activity than both the control and the Atx1[30Q] strains 
(Fig. 3.13A and 3.14A, C). At 12 dpf, both the Atx1[30Q] and the Atx1[82Q] strains showed 
weaker activity than the control strain (Fig. 3.13B and 3.14B, D). The activity was assessed 
by the detection of calcium-transient activity during spontaneous PC activities over time. 
Fernandez-Funez and coworkers showed that not only the human pathogenic allele 
Atx1[82Q], but also the high levels of human non-pathogenic allele Atx1[30Q] induced a 
similar neurodegenerative phenotype in PCs of transgenic mice. The difference was just that 
the pathology of such high levels of the human wild-type allele Atx1[30Q] required longer 
time to appear. The pathology of Atx1[82Q] appeared in the 12-15 week old mice, but the 
pathology of Atx1[30Q] started to be seen in the 59 week old mice (Fernandez-Funez et al. 
2000). The current physiology results at 6 and 12 dpf build on this existing evidence as the 
neuronal-activity data in zebrafish revealed that overexpression of the human wild-type gene 
Atx1[30Q] in PCs caused a pathological phenotype similar to the phenotype induced by the 
human mutant gene Atx1[82Q]. The only difference was also that the pathology of Atx1[30Q] 
was seen at 12 dpf, later than the pathology of Atx1[82Q] which appeared already as early as 
6 dpf (Fig. 3.13 and 3.14). 
Furthermore, interesting results were shown in a polyQ disease model for SCA7 in zebrafish. 




consequently impaired the differentiation of PCs (Yanicostas et al. 2012). This loss-of-
function disease model is quite different from the current gain-of-function disease model, but 
both SCA models display a neurodegenerative phenotype of zebrafish PCs. In keeping with 
the pathophysiological alteration in SCA1 zebrafish at 6 dpf (Fig. 3.13A and 3.14A, C), a 
pathological phenotype was also observed in PCs of SCA7 zebrafish at an early larval stage (5 
dpf). However, such pathological phenotype in SCA7 zebrafish was not just physiological 
changes in PCs, but a severe reduction in the number of PCs as early as 5 dpf was reported. 
In addition, a marked decrease was indicated in the number of PCs expressing retinoid-related 
orphan nuclear receptor α (RORα), a transcription factor belonging to the family of retinoid-
related orphan nuclear-receptors and critical for proper differentiation of PCs (Yanicostas et al. 
2012). Interestingly, such down regulation of RORα was also observed in the hAtx1[82Q] 
knock-in neurodegeneration mouse model of SCA1 (Serra et al. 2006). Moreover, a down 
regulation of the genes controlled by RORα was reported. It was concluded that the decreased 
expression of RORα enhanced the hAtx1[82Q] toxicity and that the down regulation of RORα-
mediated genes during development is a key factor in the vulnerability of PCs to SCA1. 
Therefore, Serra and his colleagues suggested that the failure of neurons to entirely develop, 
even in the absence of an immediate phenotype, can lead to a weaker ability of adult neurons 
to survive. This interpretation might also be convenient for the results of the current study as 
the late juvenile and adult neurons were not able to survive (Fig. 3.6 and 3.7), although the 
immediate effect of the pathogenic allele hAtx1[82Q] on PCs at the early larval stages was not 
very robust. Therefore, RORα needs to be investigated in the current zebrafish model as it 
could be down regulated during the development of the hAtx1[82Q]-expressing transgenic 
zebrafish. Such down regulation might have played a role in the altered neuronal activity of 
PCs at the 6 and 12 dpf larval stages (Fig. 3.13 and 3.14) and consequently the later 









4.4 Behavioral abnormalities in the SCA1 zebrafish model 
PolyQ SCA disorders display progredient degeneration of the cerebellum and its related 
structures which results in progredient ataxia in addition to other diverse symptoms 
(Niewiadomska-Cimicka et al. 2020). SCA1 patients suffer from behavioral deficits that do 
not only comprise locomotor control defects (ataxia), but also cognitive and emotional defects 
(Mastammanavar et al. 2020). Interestingly, SCA1 zebrafish displayed also behavioral deficits. 
In the current study, robust behavioral abnormalities were observed in the zebrafish model of 
SCA1 in terms of exploratory behavior. Late juveniles as well as adults that demonstrated 
robust neurodegeneration of PCs displayed a reduced-exploration phenotype. Such phenotype 
was observed starting from 2 mpf along with the loss of PCs and got worse at 3 mpf with the 
stronger loss of PCs (Fig. 3.15, 3.16 and 3.17). However, the reduced-exploration phenotype 
was not observed in early juvenile SCA1 fish at 40 dpf most likely due to less-pronounced PC 
degeneration. This affected exploratory behavior might reflect an anxiety-related phenotype 
reminiscent of non-ataxic phenotypes observed in SCA1-affected patients (Egan et al. 2009; 
Mastammanavar et al. 2020). 
In terms of locomotion, no gross locomotor deficits in zebrafish expressing the human 
pathogenic protein Atx1[82Q] were observed neither at juveniles nor at adults (Fig. 3.18), 
despite the robust loss of PCs. The regular growth of body size observed in SCA1 zebrafish 
also suggests that they do not seem to have major locomotor deficits interfering with proper 
feeding (Fig 3.11). Moreover, the ability of SCA1 fish to mate reflects a proper motor 
coordination. Since the loss of PCs in the SCA1 zebrafish was observed to be more robust in 
the anterior region of the PCL (Fig. 3.8c), the unaffected locomotor behavior might be due to 
the less-pronounced PC degeneration in the medial and dorsal regions of the PCL (Fig. 3.8c). 
This finding fits to recent results from the Köster lab which demonstrated that PCs in the 
anterior cerebellum do not show neuronal activity during swimming like PCs in the medial 





Figure 4.1 Signals of genetically-encoded calcium indicator in the Purkinje cell layer reveal 
the spatially distinct regions responding to different behavioral paradigms 
The figure displays the PC neuronal activity during optomotor response (OMR, red) 
and optokinetic response (OKR, yellow). It is noticed that there is almost no calcium 
activity in the anterior PC region during OMR. The image is representative for the 
experimental group (n = 10/group) and display a dorsal view of larval zebrafish 
cerebellum (6 dpf), anterior is to the left (Matsui et al. 2014).  
 
In the previously-established polyQ disease model in zebrafish for SCA3 (Machado–Joseph) 
disease, where either the human non-pathogenic Atx3[23Q] or disease causing Atx3[84Q] 
genes were expressed in zebrafish neurons (Watchon et al. 2017) under control of a HuC 
(elav) neuronal specific promoter (Park et al. 2000), the locomotor behavior results were 
different. Watchon and his colleagues indicated motor impairment in the Atx3[84Q] zebrafish 
that swam shorter distances than the Atx3[23Q] zebrafish in an open field behavioral test as 
early as 6 dpf. However, no significant differences were observed between Atx1[30Q] and 
Atx1[82Q] zebrafish in terms of the distance swum in the novel tank diving test until the adult 
stage (3 mpf) (Fig. 3.18A). Watchon and his colleagues explained that the locomotor deficits 
they observed are driven by expression of the human mutant Atx3[84Q] gene in all zebrafish 
neurons including the motor neurons. In the current SCA1 model expressing the human mutant 
polyQ gene Atx1[82Q] exclusively in PCs and showing less-pronounced PC loss in the medial 
and dorsal regions, the exploratory behavior has been affected without major detectable effects 






4.5 Conclusion and outlook 
In this study, zebrafish is introduced to the ataxia research community as a novel SCA1 
genetic model with unique characteristics. This neurodegeneration model in zebrafish, 
mimicking human SCA1 pathology, is a powerful tool to reveal in vivo the causative 
mechanisms of cytotoxicity in SCA1, a neurodegenerative disease for which no cure at 
present exists. Zebrafish SCA1 model allows for observing affected PCs using fluorescent 
protein reporters and biosensors and for monitoring the behavioral performance of affected 
fish in relation to their disease progression. With the accessibility for in vivo imaging 
approaches, these SCA1 zebrafish provide a model to interconnect cellular and molecular 
pathological mechanisms of PC degeneration with physiological and behavioral studies to 
offer longitudinal structure-function-behavior relationship insights. The region-specific PC 
contributions to cerebellar neurodegeneration phenotypes can also be investigated. 
Furthermore, this model can be used for validating potential compounds against such a 
devastative neurological disease for their efficacy, blood brain barrier passage and side 
effects.  
In order to perform future studies on this model, it is very important to use the proper control 
transgenic strains. Therefore, depending on the results of this study that showed physiological 
abnormalities in PCs of the Atx1[30Q] transgenic strain expressing the human non-pathogenic 
allele Atx1[30Q], it is recommended to use an additional control strain. The additional control 
transgenic strain used in this study which expresses only a fluorescent reporter protein is a 
good candidate. A transgenic strain expressing an engineered human Atx1 allele with a shorter 
polyQ tract might be also a good candidate control strain. 
The interaction of the Atx1 protein with the proteins involved in the SCA1 pathology such as 
CIC and RBM17 needs to be studied in zebrafish PCs to investigate how the 
neurodegeneration happened. Furthermore, motor coordination as well as learning of SCA1 
zebrafish needs to be investigated in detail for further characterization of the model. A swim 
channel test is recommended for evaluating locomotor control of the fish against water current 
with gradually increasing speed (rheotaxis), and classical and operant conditioning tests are 





It is suggested using 6-dpf larval SCA1 zebrafish for compound-screening studies as it is a 
good transparent model accessible for in vivo bioimaging and it displays an early 
pathophysiological phenotype to be investigated. Ultimately, this track of research, aiming at 
modeling neurodegenerative disorders in such cheaply-maintained small vertebrate animal 
with large amounts of easily-accessible embryos and larvae as well as rapid development, 
could lead to faster discovery of the pathological mechanisms underlying these disorders and 
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